{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 373,
   "id": "cd365676-8285-4bfc-a1fe-93fd31ff92cb",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "def read_file(file):\n",
    "\twith open(file, \"r\") as fp:\n",
    "\t    data = json.load(fp)\n",
    "\treturn data\n",
    "    \n",
    "biomarkers = read_file(\"referenced/biomarkers.json\")\n",
    "indications = read_file(\"data/indications.json\")\n",
    "therapies = read_file(\"referenced/therapies.json\")\n",
    "diseases = read_file(\"referenced/diseases.json\")\n",
    "propositions = read_file(\"referenced/propositions.json\")\n",
    "contributions = read_file(\"referenced/contributions.json\")\n",
    "strength = read_file(\"referenced/strengths.json\")\n",
    "documents = read_file(\"data/documents.json\")\n",
    "statements = read_file(\"data/statements.hc.json\")\n",
    "therapy_groups = read_file(\"referenced/therapy_groups.json\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 374,
   "id": "6a751d62-44dd-465a-acc2-1acc8943e634",
   "metadata": {},
   "outputs": [],
   "source": [
    "therapy_lookup = {item[\"id\"]: item for item in therapies}\n",
    "disease_lookup = {item[\"id\"]: item for item in diseases}\n",
    "biomarker_lookup = {item[\"id\"]: item for item in biomarkers}\n",
    "strength_lookup = {item[\"id\"]: item for item in strength}\n",
    "contribution_lookup = {item[\"id\"]: item for item in contributions}\n",
    "document_lookup = {doc[\"id\"]: doc for doc in documents}\n",
    "indication_lookup = {ind[\"id\"]: ind for ind in indications}\n",
    "therapy_groups_lookup = {item[\"id\"]: item for item in therapy_groups}\n",
    "proposition_lookup = {item['id']: item for item in propositions}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 375,
   "id": "56022c16-68c6-4ece-82fa-60a1333372b7",
   "metadata": {},
   "outputs": [],
   "source": [
    "def dereference_propositions(propositions, therapy_lookup, disease_lookup, biomarker_lookup, therapy_groups_lookup):\n",
    "    dereferenced_props = []\n",
    "    for prop in propositions:\n",
    "        prop = prop.copy()\n",
    "\n",
    "        if prop[\"therapy_id\"] != None:\n",
    "            prop[\"therapy\"] = therapy_lookup[prop[\"therapy_id\"]]\n",
    "            prop.pop(\"therapy_id\")\n",
    "        elif prop[\"therapy_group_id\"] != None:\n",
    "            therapy_group = therapy_groups_lookup[prop[\"therapy_group_id\"]]\n",
    "            prop[\"therapy_group\"] = therapy_group\n",
    "            dereferenced_therapiesG = []\n",
    "            for TGid in therapy_group[\"therapies\"]:\n",
    "                dereferenced_therapiesG.append(therapy_lookup[TGid])\n",
    "            prop[\"therapies\"] = dereferenced_therapiesG\n",
    "            prop.pop(\"therapy_group_id\")\n",
    "        else: \n",
    "            print(\"Unexpected input in proposition\")\n",
    "\n",
    "        condition_id = prop.pop(\"conditionQualifier_id\")\n",
    "        prop[\"conditionQualifier\"] = disease_lookup[condition_id]\n",
    "\n",
    "        resolved_biomarkers = []\n",
    "        for bio in prop[\"biomarkers\"]:\n",
    "            resolved_biomarkers.append(biomarker_lookup[bio])\n",
    "        prop[\"biomarkers\"] = resolved_biomarkers\n",
    "\n",
    "        dereferenced_props.append(prop)\n",
    "    return dereferenced_props\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 376,
   "id": "cb939ca0-bf87-46aa-aabd-1fbce5b9594e",
   "metadata": {},
   "outputs": [],
   "source": [
    "#print(dereference_propositions(propositions, therapy_lookup, disease_lookup, biomarker_lookup, therapy_groups_lookup))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 377,
   "id": "7a1f7792-d055-41c8-a827-ae8938925bfd",
   "metadata": {},
   "outputs": [],
   "source": [
    "dereferenced_props = dereference_propositions(propositions, therapy_lookup, disease_lookup, biomarker_lookup, therapy_groups_lookup)\n",
    "dereferenced_prop_lookup = {prop[\"id\"]: prop for prop in dereferenced_props}\n",
    "null_count = 0 \n",
    "statement_count = 0 \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 393,
   "id": "10a52b00-7170-4328-a5b4-3eb202a658ce",
   "metadata": {},
   "outputs": [],
   "source": [
    "def dereference_statements(statements, dereferenced_prop_lookup, strength_lookup, indication_lookup, contribution_lookup, document_lookup):\n",
    "    dereferenced_statements = []\n",
    "    global null_count, statement_count\n",
    "    null_count = 0 \n",
    "    statement_count = 0\n",
    "    for state in statements:\n",
    "        state = state.copy()\n",
    "        proposition_id = state[\"proposition_id\"]\n",
    "\n",
    "        if proposition_id == \"\":\n",
    "            print(\"Skipping statement with empty proposition_id, statement_id:\" + str(state[\"id\"]))\n",
    "        elif proposition_id == None:\n",
    "            print(\"Null value in prop idea for statement_id:\" + str(state[\"id\"]))\n",
    "            strength_id = state.pop(\"strength_id\")\n",
    "            state[\"strength\"] = strength_lookup[strength_id]\n",
    "\n",
    "            indication_id = state.pop(\"indication_id\")\n",
    "            state[\"indication\"] = indication_lookup[indication_id]\n",
    "\n",
    "            contributions_resolved = []\n",
    "            for contrib_id in state[\"contributions\"]:\n",
    "                contributions_resolved.append(contribution_lookup[contrib_id])\n",
    "            state[\"contributions\"] = contributions_resolved\n",
    "\n",
    "            documents_resolved = []\n",
    "            for doc_id in state[\"reportedIn\"]:\n",
    "                documents_resolved.append(document_lookup[doc_id])\n",
    "            state[\"reportedIn\"] = documents_resolved\n",
    "\n",
    "            state.pop(\"proposition_id\")\n",
    "            state[\"proposition\"] = None\n",
    "\n",
    "            dereferenced_statements.append(state)\n",
    "            null_count += 1\n",
    "\n",
    "        else:\n",
    "            state.pop(\"proposition_id\")\n",
    "            state[\"proposition\"] = dereferenced_prop_lookup[proposition_id]\n",
    "\n",
    "            strength_id = state.pop(\"strength_id\")\n",
    "            state[\"strength\"] = strength_lookup[strength_id]\n",
    "\n",
    "            indication_id = state.pop(\"indication_id\")\n",
    "            state[\"indication\"] = indication_lookup[indication_id]\n",
    "\n",
    "            contributions_resolved = []\n",
    "            for contrib_id in state[\"contributions\"]:\n",
    "                contributions_resolved.append(contribution_lookup[contrib_id])\n",
    "            state[\"contributions\"] = contributions_resolved \n",
    "\n",
    "            documents_resolved = []\n",
    "            for doc_id in state[\"reportedIn\"]:\n",
    "                documents_resolved.append(document_lookup[doc_id])\n",
    "            state[\"reportedIn\"] = documents_resolved\n",
    "\n",
    "            dereferenced_statements.append(state)\n",
    "            statement_count += 1\n",
    "            \n",
    "    return dereferenced_statements\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 398,
   "id": "fb0c9eaf-d5b1-4b55-8756-80435bde4291",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "the amount of null statements is: 44\n",
      "the amount of 'correct' statements is: 196\n",
      "Null value in prop idea for statement_id:hc:2\n",
      "Null value in prop idea for statement_id:hc:3\n",
      "Null value in prop idea for statement_id:hc:28\n",
      "Null value in prop idea for statement_id:hc:16\n",
      "Null value in prop idea for statement_id:hc:44\n",
      "Null value in prop idea for statement_id:hc:48\n",
      "Null value in prop idea for statement_id:hc:68\n",
      "Null value in prop idea for statement_id:hc:70\n",
      "Null value in prop idea for statement_id:hc:71\n",
      "Null value in prop idea for statement_id:hc:77\n",
      "Null value in prop idea for statement_id:hc:77\n",
      "Null value in prop idea for statement_id:hc:81\n",
      "Null value in prop idea for statement_id:hc:82\n",
      "Null value in prop idea for statement_id:hc:83\n",
      "Null value in prop idea for statement_id:hc:84\n",
      "Null value in prop idea for statement_id:hc:85\n",
      "Null value in prop idea for statement_id:hc:137\n",
      "Null value in prop idea for statement_id:hc:138\n",
      "Null value in prop idea for statement_id:hc:139\n",
      "Null value in prop idea for statement_id:hc:140\n",
      "Null value in prop idea for statement_id:hc:150\n",
      "Null value in prop idea for statement_id:hc:151\n",
      "Null value in prop idea for statement_id:hc:153\n",
      "Null value in prop idea for statement_id:hc:154\n",
      "Null value in prop idea for statement_id:hc:155\n",
      "Null value in prop idea for statement_id:hc:156\n",
      "Null value in prop idea for statement_id:hc:157\n",
      "Null value in prop idea for statement_id:hc:158\n",
      "Null value in prop idea for statement_id:hc:166\n",
      "Null value in prop idea for statement_id:hc:168\n",
      "Null value in prop idea for statement_id:hc:169\n",
      "Null value in prop idea for statement_id:hc:171\n",
      "Null value in prop idea for statement_id:hc:172\n",
      "Null value in prop idea for statement_id:hc:171\n",
      "Null value in prop idea for statement_id:hc:199\n",
      "Null value in prop idea for statement_id:hc:200\n",
      "Null value in prop idea for statement_id:hc:201\n",
      "Null value in prop idea for statement_id:hc:202\n",
      "Null value in prop idea for statement_id:hc:207\n",
      "Null value in prop idea for statement_id:hc:208\n",
      "Null value in prop idea for statement_id:hc:222\n",
      "Null value in prop idea for statement_id:hc:223\n",
      "Null value in prop idea for statement_id:hc:224\n",
      "Null value in prop idea for statement_id:hc:225\n",
      "Skipping statement with empty proposition_id, statement_id:hc:226\n",
      "Skipping statement with empty proposition_id, statement_id:hc:115\n",
      "Skipping statement with empty proposition_id, statement_id:hc:115\n",
      "Skipping statement with empty proposition_id, statement_id:hc:115\n",
      "Skipping statement with empty proposition_id, statement_id:hc:115\n",
      "Skipping statement with empty proposition_id, statement_id:hc:115\n",
      "Skipping statement with empty proposition_id, statement_id:hc:115\n",
      "Skipping statement with empty proposition_id, statement_id:hc:115\n",
      "Skipping statement with empty proposition_id, statement_id:hc:115\n",
      "Skipping statement with empty proposition_id, statement_id:hc:115\n",
      "[{'id': 'hc:0', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [product monograph]. HC.', 'aliases': [], 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2025-04-08', 'url': 'https://pdf.hres.ca/dpd_pm/00080158.PDF', 'url_drug': 'https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 48, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 0, 'type': 'CategoricalVariant', 'name': 'CD30 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD30'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 11, 'membershipOperator': 'AND', 'therapies': [0, 59, 2, 122]}, 'therapies': [{'id': 0, 'conceptType': 'Drug', 'name': 'Brentuximab Vedotin', 'primary_coding_id': 'ncit:C66944', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['target CD30 antigens'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primary_coding_id': 'ncit:C405', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primary_coding_id': 'ncit:C456', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primary_coding_id': 'ncit:C770', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 3, 'conceptType': 'Disease', 'name': 'Anaplastic Large Cell Lymphoma', 'primary_coding_id': 'oncotree:ALCL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.adcetris:0', 'document_id': 'doc:hc.adcetris', 'indication': 'ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.', 'raw_biomarkers': 'CD30-expressing', 'raw_cancer_type': 'systemic anaplastic large cell lymphoma (sALCL), CD30-expression peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), CD30-expression angioimmunoblastic T-cell lymphoma (AITL)', 'raw_therapeutics': 'Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, and prednisone (CHP)'}}, {'id': 'hc:26', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [product monograph]. HC.', 'aliases': [], 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2025-04-08', 'url': 'https://pdf.hres.ca/dpd_pm/00080158.PDF', 'url_drug': 'https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 48, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 0, 'type': 'CategoricalVariant', 'name': 'CD30 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD30'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 11, 'membershipOperator': 'AND', 'therapies': [0, 59, 2, 122]}, 'therapies': [{'id': 0, 'conceptType': 'Drug', 'name': 'Brentuximab Vedotin', 'primary_coding_id': 'ncit:C66944', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['target CD30 antigens'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primary_coding_id': 'ncit:C405', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primary_coding_id': 'ncit:C456', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primary_coding_id': 'ncit:C770', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 3, 'conceptType': 'Disease', 'name': 'Anaplastic Large Cell Lymphoma', 'primary_coding_id': 'oncotree:ALCL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.adcetris:0', 'document_id': 'doc:hc.adcetris', 'indication': 'ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.', 'raw_biomarkers': 'CD30-expressing', 'raw_cancer_type': 'systemic anaplastic large cell lymphoma (sALCL), CD30-expression peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), CD30-expression angioimmunoblastic T-cell lymphoma (AITL)', 'raw_therapeutics': 'Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, and prednisone (CHP)'}}, {'id': 'hc:27', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [product monograph]. HC.', 'aliases': [], 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2025-04-08', 'url': 'https://pdf.hres.ca/dpd_pm/00080158.PDF', 'url_drug': 'https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 48, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 0, 'type': 'CategoricalVariant', 'name': 'CD30 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD30'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 11, 'membershipOperator': 'AND', 'therapies': [0, 59, 2, 122]}, 'therapies': [{'id': 0, 'conceptType': 'Drug', 'name': 'Brentuximab Vedotin', 'primary_coding_id': 'ncit:C66944', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['target CD30 antigens'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primary_coding_id': 'ncit:C405', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primary_coding_id': 'ncit:C456', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primary_coding_id': 'ncit:C770', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 3, 'conceptType': 'Disease', 'name': 'Anaplastic Large Cell Lymphoma', 'primary_coding_id': 'oncotree:ALCL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.adcetris:0', 'document_id': 'doc:hc.adcetris', 'indication': 'ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.', 'raw_biomarkers': 'CD30-expressing', 'raw_cancer_type': 'systemic anaplastic large cell lymphoma (sALCL), CD30-expression peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), CD30-expression angioimmunoblastic T-cell lymphoma (AITL)', 'raw_therapeutics': 'Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, and prednisone (CHP)'}}, {'id': 'hc:1', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [product monograph]. HC.', 'aliases': [], 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2025-04-08', 'url': 'https://pdf.hres.ca/dpd_pm/00080158.PDF', 'url_drug': 'https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 836, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 0, 'type': 'CategoricalVariant', 'name': 'CD30 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD30'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 11, 'membershipOperator': 'AND', 'therapies': [0, 59, 2, 122]}, 'therapies': [{'id': 0, 'conceptType': 'Drug', 'name': 'Brentuximab Vedotin', 'primary_coding_id': 'ncit:C66944', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['target CD30 antigens'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primary_coding_id': 'ncit:C405', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primary_coding_id': 'ncit:C456', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primary_coding_id': 'ncit:C770', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 89, 'conceptType': 'Disease', 'name': 'Mycosis Fungoides', 'primary_coding_id': 'oncotree:MYCF', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.adcetris:1', 'document_id': 'doc:hc.adcetris', 'indication': 'ADCETRIS is indicated for the treatment of adult patients with CD30-expressing MF who have received prio systemic therapy', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved brentuximab vedotin for the treatment of adult patients with CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.', 'raw_biomarkers': 'CD30-expressing', 'raw_cancer_type': 'CD30-Expressing Mycosis Fungoides (MF)', 'raw_therapeutics': 'Adcetris (brentuximab vedotin)'}}, {'id': 'hc:2', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': '2009-12-11', 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2021-11-30', 'url': 'https://pdf.hres.ca/dpd_pm/00063824.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.afinitor:0', 'document_id': 'doc:hc.afinitor', 'indication': 'AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced breast cancer', 'raw_therapeutics': 'Afinitor (everolimus) in combination with exemestane'}, 'proposition': None}, {'id': 'hc:3', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': '2009-12-11', 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2021-11-30', 'url': 'https://pdf.hres.ca/dpd_pm/00063824.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.afinitor:0', 'document_id': 'doc:hc.afinitor', 'indication': 'AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced breast cancer', 'raw_therapeutics': 'Afinitor (everolimus) in combination with exemestane'}, 'proposition': None}, {'id': 'hc:28', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': '2009-12-11', 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2021-11-30', 'url': 'https://pdf.hres.ca/dpd_pm/00063824.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.afinitor:0', 'document_id': 'doc:hc.afinitor', 'indication': 'AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced breast cancer', 'raw_therapeutics': 'Afinitor (everolimus) in combination with exemestane'}, 'proposition': None}, {'id': 'hc:4', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.alecensaro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Alecensaro (alectinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Alecensaro (alectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078825.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Alecensaro', 'drug_name_generic': 'alectinib', 'first_published': '2016-09-29', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-03-11', 'url': 'https://pdf.hres.ca/dpd_pm/00078825.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 22, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 8, 'type': 'CategoricalVariant', 'name': 'v::ALK', 'genes': [2], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 9, 'conceptType': 'Drug', 'name': 'Alectinib', 'primary_coding_id': 'ncit:C101790', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.alecensaro:0', 'document_id': 'doc:hc.alecensaro', 'indication': 'ALECENSARO (alectinib) is indicated for the first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved alectinib for the first-line treatment of patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.', 'raw_biomarkers': 'ALK-positive', 'raw_cancer_type': 'metastatic non-small cell lung cancer', 'raw_therapeutics': 'Alecensaro (alectinib)'}}, {'id': 'hc:5', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.alunbrig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Alunbrig (brigatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Takeda Canada Inc. Alunbrig (brigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00066731.PDF. Revised July 2022. Accessed June 2025.', 'company': 'Takeda Canada Inc.', 'drug_name_brand': 'Alunbrig', 'drug_name_generic': 'brigatinib', 'first_published': '2018-07-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2022-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00066731.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96982', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 50, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 8, 'type': 'CategoricalVariant', 'name': 'v::ALK', 'genes': [2], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 10, 'conceptType': 'Drug', 'name': 'Brigatinib', 'primary_coding_id': 'ncit:C98831', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.alunbrig:0', 'document_id': 'doc:hc.alunbrig', 'indication': 'ALUNBRIG (brigatinib) is indicated as a monotherapy for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved brigatinib as monotherapy for the first-line treatment of adult patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.', 'raw_biomarkers': 'ALK-positive', 'raw_cancer_type': 'metastatic non-small cell lung cancer', 'raw_therapeutics': 'Alunbrig (brigatinib)'}}, {'id': 'hc:6', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.augtyro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Augtyro (repotrectinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Augtyro (repotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080483.PDF. Published May 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Augtyro', 'drug_name_generic': 'repotrectinib', 'first_published': '2025-05-07', 'access_date': '2025-06-23', 'organization_id': 'hc', 'publication_date': '2025-05-07', 'url': 'https://pdf.hres.ca/dpd_pm/00080483.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106076', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 368, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 62, 'type': 'CategoricalVariant', 'name': 'v::ROS1', 'genes': [50], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 134, 'conceptType': 'Drug', 'name': 'Repotrectinib', 'primary_coding_id': 'ncit:C133821', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['ROS inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.augtyro:0', 'document_id': 'doc:hc.augtyro', 'indication': 'AUGTYRO (repotrectinib capsules) is indicated for treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).', 'raw_biomarkers': 'ROS1-positive', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer', 'raw_therapeutics': 'Augtyro (repotrectinib)'}}, {'id': 'hc:7', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 124, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 99, 'type': 'CategoricalVariant', 'name': 'FGFR3 p.R248C', 'genes': [24], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 1803564}, {'name': 'end_position', 'value': 1803564}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.742C>T'}, {'name': 'protein_change', 'value': 'p.R248C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 6}, {'name': 'rsid', 'value': 'rs121913482'}, {'name': 'hgvsg', 'value': '4:g.1803564C>T'}, {'name': 'hgvsc', 'value': 'ENST00000260795.2:c.742C>T'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 110, 'conceptType': 'Drug', 'name': 'Erdafitinib', 'primary_coding_id': 'ncit:C103273', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 8, 'conceptType': 'Disease', 'name': 'Bladder Urothelial Carcinoma', 'primary_coding_id': 'oncotree:BLCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.balversa:0', 'document_id': 'doc:hc.balversa', 'indication': 'BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'susceptible FGFR3 genetic alterations', 'raw_cancer_type': 'locally advanced unresectable or metastatic urothelial carcinoman (UC)', 'raw_therapeutics': 'Balversa (erdafitinib)'}}, {'id': 'hc:8', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 125, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 100, 'type': 'CategoricalVariant', 'name': 'FGFR3 p.S249C', 'genes': [24], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 1803568}, {'name': 'end_position', 'value': 1803568}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.746C>G'}, {'name': 'protein_change', 'value': 'p.S249C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 6}, {'name': 'rsid', 'value': 'rs121913483'}, {'name': 'hgvsg', 'value': '4:g.1803568C>G'}, {'name': 'hgvsc', 'value': 'ENST00000260795.2:c.746C>G'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 110, 'conceptType': 'Drug', 'name': 'Erdafitinib', 'primary_coding_id': 'ncit:C103273', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 8, 'conceptType': 'Disease', 'name': 'Bladder Urothelial Carcinoma', 'primary_coding_id': 'oncotree:BLCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.balversa:0', 'document_id': 'doc:hc.balversa', 'indication': 'BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'susceptible FGFR3 genetic alterations', 'raw_cancer_type': 'locally advanced unresectable or metastatic urothelial carcinoman (UC)', 'raw_therapeutics': 'Balversa (erdafitinib)'}}, {'id': 'hc:9', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 126, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 101, 'type': 'CategoricalVariant', 'name': 'FGFR3 p.G370C', 'genes': [24], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 1806089}, {'name': 'end_position', 'value': 1806089}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1108G>T'}, {'name': 'protein_change', 'value': 'p.G370C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 8}, {'name': 'rsid', 'value': 'rs121913479'}, {'name': 'hgvsg', 'value': '4:g.1806089G>T'}, {'name': 'hgvsc', 'value': 'ENST00000260795.2:c.1108G>T'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 110, 'conceptType': 'Drug', 'name': 'Erdafitinib', 'primary_coding_id': 'ncit:C103273', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 8, 'conceptType': 'Disease', 'name': 'Bladder Urothelial Carcinoma', 'primary_coding_id': 'oncotree:BLCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.balversa:0', 'document_id': 'doc:hc.balversa', 'indication': 'BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'susceptible FGFR3 genetic alterations', 'raw_cancer_type': 'locally advanced unresectable or metastatic urothelial carcinoman (UC)', 'raw_therapeutics': 'Balversa (erdafitinib)'}}, {'id': 'hc:10', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 127, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 102, 'type': 'CategoricalVariant', 'name': 'FGFR3 p.Y373C', 'genes': [24], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 1806099}, {'name': 'end_position', 'value': 1806099}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.1118A>G'}, {'name': 'protein_change', 'value': 'p.Y373C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 8}, {'name': 'rsid', 'value': 'rs121913485'}, {'name': 'hgvsg', 'value': '4:g.1806099A>G'}, {'name': 'hgvsc', 'value': 'ENST00000260795.2:c.1118A>G'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 110, 'conceptType': 'Drug', 'name': 'Erdafitinib', 'primary_coding_id': 'ncit:C103273', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 8, 'conceptType': 'Disease', 'name': 'Bladder Urothelial Carcinoma', 'primary_coding_id': 'oncotree:BLCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.balversa:0', 'document_id': 'doc:hc.balversa', 'indication': 'BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'susceptible FGFR3 genetic alterations', 'raw_cancer_type': 'locally advanced unresectable or metastatic urothelial carcinoman (UC)', 'raw_therapeutics': 'Balversa (erdafitinib)'}}, {'id': 'hc:11', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 128, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 97, 'type': 'CategoricalVariant', 'name': 'FGFR3::TACC3', 'genes': [24, 51], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 110, 'conceptType': 'Drug', 'name': 'Erdafitinib', 'primary_coding_id': 'ncit:C103273', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 8, 'conceptType': 'Disease', 'name': 'Bladder Urothelial Carcinoma', 'primary_coding_id': 'oncotree:BLCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.balversa:0', 'document_id': 'doc:hc.balversa', 'indication': 'BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'susceptible FGFR3 genetic alterations', 'raw_cancer_type': 'locally advanced unresectable or metastatic urothelial carcinoman (UC)', 'raw_therapeutics': 'Balversa (erdafitinib)'}}, {'id': 'hc:12', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.besponsa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Besponsa (inotuzumab ozogamicin) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Besponsa (inotuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077730.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Besponsa', 'drug_name_generic': 'inotuzumab ozogamicin', 'first_published': '2018-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-08', 'url': 'https://pdf.hres.ca/dpd_pm/00077730.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96383', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 168, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 13, 'type': 'CategoricalVariant', 'name': 'CD22 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD22'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 14, 'conceptType': 'Drug', 'name': 'Inotuzumab ozogamicin', 'primary_coding_id': 'ncit:C71542', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 0, 'conceptType': 'Disease', 'name': 'Acute Lymphoid Leukemia', 'primary_coding_id': 'oncotree:ALL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.besponsa:0', 'document_id': 'doc:hc.besponsa', 'indication': 'BESPONSA (inotuzumab ozogamicin for injection) is indicated for monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved inotuzumab ozogamicin as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).', 'raw_biomarkers': 'CD22-positive', 'raw_cancer_type': 'B-cell precursor acute lymphoblastic leukemia', 'raw_therapeutics': 'Besponsa (inotuzumab ozogamicin)'}}, {'id': 'hc:13', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.blincyto', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Blincyto (blinatumomab) [product monograph]. HC.', 'aliases': [], 'citation': 'Amgen Canada Inc. Blincyto (blinatumomab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078156.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Amgen Canada Inc.', 'drug_name_brand': 'Blincyto', 'drug_name_generic': 'blinatumomab', 'first_published': '2015-12-22', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-12-27', 'url': 'https://pdf.hres.ca/dpd_pm/00078156.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93642', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 45, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 14, 'type': 'CategoricalVariant', 'name': 'CD19 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD19'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 15, 'conceptType': 'Drug', 'name': 'Blinatumomab', 'primary_coding_id': 'ncit:C62528', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD19 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 0, 'conceptType': 'Disease', 'name': 'Acute Lymphoid Leukemia', 'primary_coding_id': 'oncotree:ALL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.blincyto:2', 'document_id': 'doc:hc.blincyto', 'indication': 'BLINCYTO (blinatumomab for injection) is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved blinatumomab for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).', 'raw_biomarkers': 'CD19-positive', 'raw_cancer_type': 'B-cell precursor acute lymphoblastic leukemia (ALL)', 'raw_therapeutics': 'Blincyto (blinatumomab)'}}, {'id': 'hc:13', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.bosulif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Bosulif (bosutinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Bosulif (bosutinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076285.PDF. Revised July 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Bosulif', 'drug_name_generic': 'bosutinib', 'first_published': '2014-03-07', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-07-12', 'url': 'https://pdf.hres.ca/dpd_pm/00076285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90368', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 47, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 12, 'type': 'CategoricalVariant', 'name': 'BCR::ABL1', 'genes': [6, 0], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 16, 'conceptType': 'Drug', 'name': 'Bosutinib', 'primary_coding_id': 'ncit:C60809', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 13, 'conceptType': 'Disease', 'name': 'Chronic Myelogenous Leukemia', 'primary_coding_id': 'oncotree:CML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.bosulif:0', 'document_id': 'doc:hc.bosulif', 'indication': 'BOSULIF (bosutinib) is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved bosutinib for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).', 'raw_biomarkers': 'philadelphia chromosome-positive (Ph+)', 'raw_cancer_type': 'chronic myelogenous leukemia', 'raw_therapeutics': 'Bosulif (bosutinib)'}}, {'id': 'hc:14', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.bosulif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Bosulif (bosutinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Bosulif (bosutinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076285.PDF. Revised July 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Bosulif', 'drug_name_generic': 'bosutinib', 'first_published': '2014-03-07', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-07-12', 'url': 'https://pdf.hres.ca/dpd_pm/00076285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90368', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 47, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 12, 'type': 'CategoricalVariant', 'name': 'BCR::ABL1', 'genes': [6, 0], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 16, 'conceptType': 'Drug', 'name': 'Bosutinib', 'primary_coding_id': 'ncit:C60809', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 13, 'conceptType': 'Disease', 'name': 'Chronic Myelogenous Leukemia', 'primary_coding_id': 'oncotree:CML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.bosulif:1', 'document_id': 'doc:hc.bosulif', 'indication': 'BOSULIF (bosutinib) is indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved bosutinib for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy.', 'raw_biomarkers': 'philadelphia chromosone-positive (Ph+)', 'raw_cancer_type': 'chronic myelogenous leukemia', 'raw_therapeutics': 'Bosulif (bosutinib)'}}, {'id': 'hc:15', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2021-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-02-23', 'url': 'https://pdf.hres.ca/dpd_pm/00074711.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 41, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 16, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600E', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1799T>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 10, 'membershipOperator': 'AND', 'therapies': [17, 18]}, 'therapies': [{'id': 17, 'conceptType': 'Drug', 'name': 'Binimetinib', 'primary_coding_id': 'ncit:C84865', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primary_coding_id': 'ncit:C98283', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 40, 'conceptType': 'Disease', 'name': 'Melanoma', 'primary_coding_id': 'oncotree:MEL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.braftovi:0', 'document_id': 'doc:hc.', 'indication': 'BRAFTOVI (encorafenib) is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved encorafenib in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.', 'raw_biomarkers': 'BRAF V600E or BRAF V600K', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Braftovi (encorafenib) in combination with binimetinib'}}, {'id': 'hc:16', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2021-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-02-23', 'url': 'https://pdf.hres.ca/dpd_pm/00074711.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.braftovi:1', 'document_id': 'doc:hc.braftovi', 'indication': 'BRAFTOVI (encorafenib) is indicated, in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved encorafenib in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.', 'raw_biomarkers': 'BRAF V600E', 'raw_cancer_type': 'metastatic colorectal cancer (mCRC)', 'raw_therapeutics': 'Braftovi (encorafenib) in combination with cetuximab'}, 'proposition': None}, {'id': 'hc:17', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2021-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-02-23', 'url': 'https://pdf.hres.ca/dpd_pm/00074711.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 81, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 16, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600E', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1799T>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 16, 'membershipOperator': 'AND', 'therapies': [18, 19]}, 'therapies': [{'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primary_coding_id': 'ncit:C98283', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primary_coding_id': 'ncit:C1723', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 15, 'conceptType': 'Disease', 'name': 'Colorectal Adenocarcinoma', 'primary_coding_id': 'oncotree:COADREAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.braftovi:1', 'document_id': 'doc:hc.braftovi', 'indication': 'BRAFTOVI (encorafenib) is indicated, in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved encorafenib in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.', 'raw_biomarkers': 'BRAF V600E', 'raw_cancer_type': 'metastatic colorectal cancer (mCRC)', 'raw_therapeutics': 'Braftovi (encorafenib) in combination with cetuximab'}}, {'id': 'hc:18', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.cotellic', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Cotellic (cobimetinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Cotellic (cobimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070061.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Cotellic', 'drug_name_generic': 'cobimetinib', 'first_published': '2016-02-22', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2023-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00070061.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 82, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 16, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600E', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1799T>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 17, 'membershipOperator': 'AND', 'therapies': [21, 22]}, 'therapies': [{'id': 21, 'conceptType': 'Drug', 'name': 'Cobimetinib', 'primary_coding_id': 'ncit:C68923', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 22, 'conceptType': 'Drug', 'name': 'Vemurafenib', 'primary_coding_id': 'ncit:C64768', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 40, 'conceptType': 'Disease', 'name': 'Melanoma', 'primary_coding_id': 'oncotree:MEL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.cotellic:0', 'document_id': 'doc:hc.cotellic', 'indication': 'COTELLIC (cobimetinib) is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cobimetinib in combination wih vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'raw_biomarkers': 'BRAF V600 mutation', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Cotellic in combination with vemurafenib'}}, {'id': 'hc:19', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.cotellic', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Cotellic (cobimetinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Cotellic (cobimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070061.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Cotellic', 'drug_name_generic': 'cobimetinib', 'first_published': '2016-02-22', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2023-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00070061.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 83, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 17, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600K', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1798_1799delinsAA'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 17, 'membershipOperator': 'AND', 'therapies': [21, 22]}, 'therapies': [{'id': 21, 'conceptType': 'Drug', 'name': 'Cobimetinib', 'primary_coding_id': 'ncit:C68923', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 22, 'conceptType': 'Drug', 'name': 'Vemurafenib', 'primary_coding_id': 'ncit:C64768', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 40, 'conceptType': 'Disease', 'name': 'Melanoma', 'primary_coding_id': 'oncotree:MEL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.cotellic:0', 'document_id': 'doc:hc.cotellic', 'indication': 'COTELLIC (cobimetinib) is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cobimetinib in combination wih vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'raw_biomarkers': 'BRAF V600 mutation', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Cotellic in combination with vemurafenib'}}, {'id': 'hc:20', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2021-04-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-01-17', 'url': 'https://pdf.hres.ca/dpd_pm/00078361.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 420, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 26, 'conceptType': 'Drug', 'name': 'Trastuzumab deruxtecan', 'primary_coding_id': 'ncit:C128799', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.enhertu:0', 'document_id': 'doc:hc.enhertu', 'indication': 'ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'unresectable or metastatic breast cancer', 'raw_therapeutics': 'Enhertu (trastuzumab deruxtecan)'}}, {'id': 'hc:21', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2021-04-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-01-17', 'url': 'https://pdf.hres.ca/dpd_pm/00078361.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 420, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 26, 'conceptType': 'Drug', 'name': 'Trastuzumab deruxtecan', 'primary_coding_id': 'ncit:C128799', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.enhertu:1', 'document_id': 'doc:hc.enhertu', 'indication': 'ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1).', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'unresectable or metastatic breast cancer', 'raw_therapeutics': 'Enhertu (trastuzumab deruxtecan)'}}, {'id': 'hc:22', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2021-04-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-01-17', 'url': 'https://pdf.hres.ca/dpd_pm/00078361.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 421, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 22, 'type': 'CategoricalVariant', 'name': 'HER2-low', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Low'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 26, 'conceptType': 'Drug', 'name': 'Trastuzumab deruxtecan', 'primary_coding_id': 'ncit:C128799', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.enhertu:0', 'document_id': 'doc:hc.enhertu', 'indication': 'ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'unresectable or metastatic breast cancer', 'raw_therapeutics': 'Enhertu (trastuzumab deruxtecan)'}}, {'id': 'hc:23', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2021-04-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-01-17', 'url': 'https://pdf.hres.ca/dpd_pm/00078361.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 423, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 26, 'conceptType': 'Drug', 'name': 'Trastuzumab deruxtecan', 'primary_coding_id': 'ncit:C128799', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 2, 'conceptType': 'Disease', 'name': 'Adenocarcinoma of the Gastroesophageal Junction', 'primary_coding_id': 'oncotree:GEJ', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.enhertu:3', 'document_id': 'doc:hc.enhertu', 'indication': 'ENHERTU (trastuzumab deruxtecan) as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable,locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma', 'raw_therapeutics': 'Enhertu (trastuzumab deruxtecan)'}}, {'id': 'hc:24', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [product monograph]. HC.', 'aliases': [], 'citation': 'ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.', 'company': 'ImClone LLC', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': '2018-01-10', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2018-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00043071.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 78, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 24, 'type': 'CategoricalVariant', 'name': 'EGFR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'EGFR'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 25, 'type': 'CategoricalVariant', 'name': 'Wild type KRAS', 'genes': [31], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 14, 'membershipOperator': 'AND', 'therapies': [19, 27, 29]}, 'therapies': [{'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primary_coding_id': 'ncit:C1723', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 27, 'conceptType': 'Drug', 'name': 'Irinotecan', 'primary_coding_id': 'ncit:C62040', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase I inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primary_coding_id': 'ncit:C505', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 15, 'conceptType': 'Disease', 'name': 'Colorectal Adenocarcinoma', 'primary_coding_id': 'oncotree:COADREAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.erbitux:0', 'document_id': 'doc:hc.erbitux', 'indication': 'ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cetuximab for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment.', 'raw_biomarkers': 'EGFR-expressing, K-Ras wild type', 'raw_cancer_type': 'metastatic colorectal carcinoma (mCRC)', 'raw_therapeutics': 'Erbitux (cetuximab) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin)'}}, {'id': 'hc:25', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [product monograph]. HC.', 'aliases': [], 'citation': 'ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.', 'company': 'ImClone LLC', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': '2018-01-10', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2018-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00043071.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 79, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 24, 'type': 'CategoricalVariant', 'name': 'EGFR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'EGFR'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 25, 'type': 'CategoricalVariant', 'name': 'Wild type KRAS', 'genes': [31], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 15, 'membershipOperator': 'AND', 'therapies': [19, 27]}, 'therapies': [{'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primary_coding_id': 'ncit:C1723', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 27, 'conceptType': 'Drug', 'name': 'Irinotecan', 'primary_coding_id': 'ncit:C62040', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase I inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 15, 'conceptType': 'Disease', 'name': 'Colorectal Adenocarcinoma', 'primary_coding_id': 'oncotree:COADREAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.erbitux:1', 'document_id': 'doc:hc.erbitux', 'indication': 'ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cetuximab for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens.', 'raw_biomarkers': 'EGFR-expressing, K-Ras wild type', 'raw_cancer_type': 'metastatic colorectal carcinoma (mCRC)', 'raw_therapeutics': 'Erbitux (cetuximab) in combination with irinotecan'}}, {'id': 'hc:29', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [product monograph]. HC.', 'aliases': [], 'citation': 'ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.', 'company': 'ImClone LLC', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': '2018-01-10', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2018-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00043071.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 80, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 24, 'type': 'CategoricalVariant', 'name': 'EGFR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'EGFR'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 25, 'type': 'CategoricalVariant', 'name': 'Wild type KRAS', 'genes': [31], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primary_coding_id': 'ncit:C1723', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 15, 'conceptType': 'Disease', 'name': 'Colorectal Adenocarcinoma', 'primary_coding_id': 'oncotree:COADREAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.erbitux:2', 'document_id': 'doc:hc.erbitux', 'indication': 'ERBITUX (cetuximab) is indicated as a single agent in patients who are intolerant to irinotecan-based chemotherapy for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cetuximab as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who are intolerant to irinotecan-based chemotherapy.', 'raw_biomarkers': 'EGFR-expressing, K-Ras wild type', 'raw_cancer_type': 'metastatic colorectal carcinoma (mCRC)', 'raw_therapeutics': 'Erbitux (cetuximab) as a single agent'}}, {'id': 'hc:30', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [product monograph]. HC.', 'aliases': [], 'citation': 'ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.', 'company': 'ImClone LLC', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': '2018-01-10', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2018-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00043071.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 80, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 24, 'type': 'CategoricalVariant', 'name': 'EGFR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'EGFR'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 25, 'type': 'CategoricalVariant', 'name': 'Wild type KRAS', 'genes': [31], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primary_coding_id': 'ncit:C1723', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 15, 'conceptType': 'Disease', 'name': 'Colorectal Adenocarcinoma', 'primary_coding_id': 'oncotree:COADREAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.erbitux:3', 'document_id': 'doc:hc.erbitux', 'indication': 'ERBITUX (cetuximab) is indicated as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who have failed both irinotecan- and oxaliplatin-based regimens and who have received a fluoropyrimidine.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cetuximab as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who have failed both irinotecan- and oxaliplatin-based regimens and who have received a fluoropyrimidine.', 'raw_biomarkers': 'EGFR-expressing, K-Ras wild type', 'raw_cancer_type': 'metastatic colorectal carcinoma (mCRC)', 'raw_therapeutics': 'Erbitux (cetuximab) as a single agent'}}, {'id': 'hc:31', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Faslodex (fulvestrant) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00053975.PDF. Revised November 2019. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-11-15', 'url': 'https://pdf.hres.ca/dpd_pm/00053975.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72981', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 134, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 1, 'type': 'CategoricalVariant', 'name': 'ER positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primary_coding_id': 'ncit:C1379', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.faslodex:0', 'document_id': 'doc:hc.faslodex', 'indication': 'FASLODEX (fulvestrant) is indicated for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved fulvestrant for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.', 'raw_biomarkers': 'estrogen receptor-positive (ER+), HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Faslodex (fulvestrant)'}}, {'id': 'hc:32', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.giotrif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Giotrif (afatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Boehringer Ingelheim (Canada) Ltd. Giotrif (afatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00051644.PDF. Revised June 2019. Accessed June 2025.', 'company': 'Boehringer Ingelheim (Canada) Ltd', 'drug_name_brand': 'Giotrif', 'drug_name_generic': 'afatinib', 'first_published': None, 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2019-06-06', 'url': 'https://pdf.hres.ca/dpd_pm/00051644.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90026', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 21, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 72, 'type': 'CategoricalVariant', 'name': 'EGFR somatic variants', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': False}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 34, 'conceptType': 'Drug', 'name': 'Afatinib', 'primary_coding_id': 'ncit:C66940', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.giotrif:0', 'document_id': 'doc:hc.giotrif', 'indication': 'GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor nave patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor nave patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).', 'raw_biomarkers': 'EGFR Del 19, EGFR exon 21 L858R', 'raw_cancer_type': 'metastatic adenocarcinoma of the lung', 'raw_therapeutics': 'Giotrif (afatinib)'}}, {'id': 'hc:33', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.giotrif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Giotrif (afatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Boehringer Ingelheim (Canada) Ltd. Giotrif (afatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00051644.PDF. Revised June 2019. Accessed June 2025.', 'company': 'Boehringer Ingelheim (Canada) Ltd', 'drug_name_brand': 'Giotrif', 'drug_name_generic': 'afatinib', 'first_published': None, 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2019-06-06', 'url': 'https://pdf.hres.ca/dpd_pm/00051644.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90026', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 560, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 19, 'type': 'CategoricalVariant', 'name': 'EGFR oncogenic variants', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 34, 'conceptType': 'Drug', 'name': 'Afatinib', 'primary_coding_id': 'ncit:C66940', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.giotrif:0', 'document_id': 'doc:hc.giotrif', 'indication': 'GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor nave patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor nave patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).', 'raw_biomarkers': 'EGFR Del 19, EGFR exon 21 L858R', 'raw_cancer_type': 'metastatic adenocarcinoma of the lung', 'raw_therapeutics': 'Giotrif (afatinib)'}}, {'id': 'hc:34', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 158, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 12, 'type': 'CategoricalVariant', 'name': 'BCR::ABL1', 'genes': [6, 0], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 41, 'conceptType': 'Drug', 'name': 'Imatinib', 'primary_coding_id': 'ncit:C62035', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 13, 'conceptType': 'Disease', 'name': 'Chronic Myelogenous Leukemia', 'primary_coding_id': 'oncotree:CML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:0', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with newly diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with newly diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.', 'raw_biomarkers': 'philadelphia chromosome-positive', 'raw_cancer_type': 'chronic myeloid leukemia', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:35', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 158, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 12, 'type': 'CategoricalVariant', 'name': 'BCR::ABL1', 'genes': [6, 0], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 41, 'conceptType': 'Drug', 'name': 'Imatinib', 'primary_coding_id': 'ncit:C62035', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 13, 'conceptType': 'Disease', 'name': 'Chronic Myelogenous Leukemia', 'primary_coding_id': 'oncotree:CML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:1', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase, or in chronic phase after failure of interferon-alpha therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase, or in chronic phase after failure of interferon-alpha therapy.', 'raw_biomarkers': 'Philadelphia chromosome-positive', 'raw_cancer_type': 'chronic myeloid leukemia (CML)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:36', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 160, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 12, 'type': 'CategoricalVariant', 'name': 'BCR::ABL1', 'genes': [6, 0], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 41, 'conceptType': 'Drug', 'name': 'Imatinib', 'primary_coding_id': 'ncit:C62035', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 0, 'conceptType': 'Disease', 'name': 'Acute Lymphoid Leukemia', 'primary_coding_id': 'oncotree:ALL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:2', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate ', 'raw_biomarkers': 'Philadelphia chromosome-positive', 'raw_cancer_type': 'acute lymphoblastic leukemia', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:37', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 160, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 12, 'type': 'CategoricalVariant', 'name': 'BCR::ABL1', 'genes': [6, 0], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 41, 'conceptType': 'Drug', 'name': 'Imatinib', 'primary_coding_id': 'ncit:C62035', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 0, 'conceptType': 'Disease', 'name': 'Acute Lymphoid Leukemia', 'primary_coding_id': 'oncotree:ALL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:3', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.', 'raw_biomarkers': 'Philadelphia chromosome-positive', 'raw_cancer_type': 'acute lymphoblastic leukemia (Ph+ALL)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:38', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 161, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 28, 'type': 'CategoricalVariant', 'name': 'PDGFRA rearrangements', 'genes': [39], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': None}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 41, 'conceptType': 'Drug', 'name': 'Imatinib', 'primary_coding_id': 'ncit:C62035', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 43, 'conceptType': 'Disease', 'name': 'Myelodysplastic Syndromes', 'primary_coding_id': 'oncotree:MDS', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:4', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'raw_biomarkers': 'DGFR gene re-arrangements', 'raw_cancer_type': 'myelodysplastic/myeloproliferative diseases (MDS/MPD)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:39', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 162, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 29, 'type': 'CategoricalVariant', 'name': 'PDGFRB rearrangements', 'genes': [40], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': None}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 41, 'conceptType': 'Drug', 'name': 'Imatinib', 'primary_coding_id': 'ncit:C62035', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 43, 'conceptType': 'Disease', 'name': 'Myelodysplastic Syndromes', 'primary_coding_id': 'oncotree:MDS', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:4', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'raw_biomarkers': 'DGFR gene re-arrangements', 'raw_cancer_type': 'myelodysplastic/myeloproliferative diseases (MDS/MPD)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:40', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 580, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 28, 'type': 'CategoricalVariant', 'name': 'PDGFRA rearrangements', 'genes': [39], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': None}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 41, 'conceptType': 'Drug', 'name': 'Imatinib', 'primary_coding_id': 'ncit:C62035', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 45, 'conceptType': 'Disease', 'name': 'Myeloproliferative Neoplasm', 'primary_coding_id': 'oncotree:MPN', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:4', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'raw_biomarkers': 'DGFR gene re-arrangements', 'raw_cancer_type': 'myelodysplastic/myeloproliferative diseases (MDS/MPD)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:41', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 581, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 29, 'type': 'CategoricalVariant', 'name': 'PDGFRB rearrangements', 'genes': [40], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': None}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 41, 'conceptType': 'Drug', 'name': 'Imatinib', 'primary_coding_id': 'ncit:C62035', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 45, 'conceptType': 'Disease', 'name': 'Myeloproliferative Neoplasm', 'primary_coding_id': 'oncotree:MPN', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:4', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'raw_biomarkers': 'DGFR gene re-arrangements', 'raw_cancer_type': 'myelodysplastic/myeloproliferative diseases (MDS/MPD)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:42', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 163, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 122, 'type': 'CategoricalVariant', 'name': 'KIT p.D816V', 'genes': [30], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 55599321}, {'name': 'end_position', 'value': 55599321}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.2447A>T'}, {'name': 'protein_change', 'value': 'p.D816V'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 17}, {'name': 'rsid', 'value': 'rs121913507'}, {'name': 'hgvsg', 'value': '4:g.55599321A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288135.5:c.2447A>T'}, {'name': '_present', 'value': False}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 41, 'conceptType': 'Drug', 'name': 'Imatinib', 'primary_coding_id': 'ncit:C62035', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 42, 'conceptType': 'Disease', 'name': 'Aggressive Systemic Mastocytosis', 'primary_coding_id': 'oncotree:ASM', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:5', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SMAHNMD) without the D816V c-Kit mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SMAHNMD) without the D816V c-Kit mutation.', 'raw_biomarkers': 'without D816V c-Kit mutation or with the c-Kit mutational status unknown', 'raw_cancer_type': 'systemic mastocytosis (ASM and SMAHNMD)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:43', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 164, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 30, 'type': 'CategoricalVariant', 'name': 'FIP1L1::PDGFRA', 'genes': [25, 39], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 41, 'conceptType': 'Drug', 'name': 'Imatinib', 'primary_coding_id': 'ncit:C62035', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 12, 'conceptType': 'Disease', 'name': 'Chronic Eosinophilic Leukemia, NOS', 'primary_coding_id': 'oncotree:CELNOS', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:6', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR rearrangement.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR rearrangement.', 'raw_biomarkers': 'FIP1L1::PDGFRA rearrangement', 'raw_cancer_type': 'advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:41', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 165, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 31, 'type': 'CategoricalVariant', 'name': 'CD117 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD117'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 41, 'conceptType': 'Drug', 'name': 'Imatinib', 'primary_coding_id': 'ncit:C62035', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 22, 'conceptType': 'Disease', 'name': 'Gastrointestinal Stromal Tumor', 'primary_coding_id': 'oncotree:GIST', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:7', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).', 'raw_biomarkers': 'Kit (CD117) positive', 'raw_cancer_type': 'unresectable and/or metastatic malignant gastrointestinal stromal tumors', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:42', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 165, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 31, 'type': 'CategoricalVariant', 'name': 'CD117 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD117'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 41, 'conceptType': 'Drug', 'name': 'Imatinib', 'primary_coding_id': 'ncit:C62035', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 22, 'conceptType': 'Disease', 'name': 'Gastrointestinal Stromal Tumor', 'primary_coding_id': 'oncotree:GIST', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:8', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.', 'raw_biomarkers': 'Kit (CD117) positive', 'raw_cancer_type': 'gastrointestinal stromal tumors (GIST)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:43', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 418, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primary_coding_id': 'ncit:C1647', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.herceptin:0', 'document_id': 'doc:hc.herceptin', 'indication': 'HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy.', 'raw_biomarkers': 'HER2-overexpressing', 'raw_cancer_type': 'early stage breast cancer', 'raw_therapeutics': 'Herceptin (trastuzumab)'}}, {'id': 'hc:44', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.herceptin:1', 'document_id': 'doc:hc.herceptin', 'indication': 'HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab in combination with paclitaxel or docetaxel for the treatment of early stage breast cancer patients with ECOG 0-1 status, whose tumors overexpress HER2, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide.', 'raw_biomarkers': 'HER2 overexpression', 'raw_cancer_type': 'early stage breast cancer', 'raw_therapeutics': 'Herceptin (trastuzumab), paclitaxel, docetaxel'}, 'proposition': None}, {'id': 'hc:45', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 563, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 112, 'membershipOperator': 'AND', 'therapies': [37, 24, 25]}, 'therapies': [{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primary_coding_id': 'ncit:C1282', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primary_coding_id': 'ncit:C1526', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primary_coding_id': 'ncit:C1647', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.herceptin:2', 'document_id': 'doc:hc.herceptin', 'indication': 'HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab in combination with docetaxel and carboplatin for the treatment of early stage breast cancer patients with ECOG 0-1 status, whose tumors overexpress HER2.', 'raw_biomarkers': 'HER2 overexpression', 'raw_cancer_type': 'early stage breast cancer', 'raw_therapeutics': 'Herceptin (trastuzumab), docetaxel, carboplatin'}}, {'id': 'hc:46', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 418, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primary_coding_id': 'ncit:C1647', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.herceptin:3', 'document_id': 'doc:hc.herceptin', 'indication': 'HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with metastatic breast cancer (MBC) whose tumours overexpress HER2.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab for metastatic breast cancer in patients whose tumors overexpress HER2.', 'raw_biomarkers': 'HER2-overexpressing', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Herceptin (trastuzumab)'}}, {'id': 'hc:47', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 351, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 65, 'membershipOperator': 'AND', 'therapies': [24, 75, 25]}, 'therapies': [{'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primary_coding_id': 'ncit:C1526', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primary_coding_id': 'ncit:C38692', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primary_coding_id': 'ncit:C1647', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.herceptin:4', 'document_id': 'doc:hc.herceptin', 'indication': 'HERCEPTIN (trastuzumab for injection) can be used in combination with pertuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab in combination with pertuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Herceptin (trastuzumab), pertuzumab, docetaxel'}}, {'id': 'hc:48', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.herceptin:5', 'document_id': 'doc:hc.herceptin', 'indication': 'HERCEPTIN (trastuzumab for injection) in combination with capecitabine or intravenous 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab in combination with capecitabine or intravenous 5-fluorouracil and cisplatin for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction in patients who have not received prior anti-cancer treatment for metastatic disease.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'metastatic adenocarcinoma of the stomach or gastro-esophageal junction', 'raw_therapeutics': 'Herceptin (trastuzumab), capecitabine, 5-fluorouracil, cisplatin'}, 'proposition': None}, {'id': 'hc:49', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 311, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 1, 'type': 'CategoricalVariant', 'name': 'ER positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 49, 'membershipOperator': 'AND', 'therapies': [40, 31]}, 'therapies': [{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primary_coding_id': 'ncit:C1527', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primary_coding_id': 'ncit:C49176', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.ibrance:0', 'document_id': 'doc:hc.ibrance', 'indication': 'IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.', 'raw_biomarkers': 'HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Ibrance (palbociclib), aromatase inhibitor'}}, {'id': 'hc:50', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 312, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}, {'id': 3, 'type': 'CategoricalVariant', 'name': 'PR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 49, 'membershipOperator': 'AND', 'therapies': [40, 31]}, 'therapies': [{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primary_coding_id': 'ncit:C1527', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primary_coding_id': 'ncit:C49176', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.ibrance:0', 'document_id': 'doc:hc.ibrance', 'indication': 'IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.', 'raw_biomarkers': 'HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Ibrance (palbociclib), aromatase inhibitor'}}, {'id': 'hc:51', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 313, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 1, 'type': 'CategoricalVariant', 'name': 'ER positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}, {'id': 3, 'type': 'CategoricalVariant', 'name': 'PR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 49, 'membershipOperator': 'AND', 'therapies': [40, 31]}, 'therapies': [{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primary_coding_id': 'ncit:C1527', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primary_coding_id': 'ncit:C49176', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.ibrance:0', 'document_id': 'doc:hc.ibrance', 'indication': 'IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.', 'raw_biomarkers': 'HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Ibrance (palbociclib), aromatase inhibitor'}}, {'id': 'hc:52', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 143, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 1, 'type': 'CategoricalVariant', 'name': 'ER positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 28, 'membershipOperator': 'AND', 'therapies': [30, 31]}, 'therapies': [{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primary_coding_id': 'ncit:C1379', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primary_coding_id': 'ncit:C49176', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.ibrance:1', 'document_id': 'doc:hc.ibrance', 'indication': 'IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.', 'raw_biomarkers': 'HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Ibrance (palbociclib), fulvestrant'}}, {'id': 'hc:53', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 144, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}, {'id': 3, 'type': 'CategoricalVariant', 'name': 'PR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 28, 'membershipOperator': 'AND', 'therapies': [30, 31]}, 'therapies': [{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primary_coding_id': 'ncit:C1379', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primary_coding_id': 'ncit:C49176', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.ibrance:1', 'document_id': 'doc:hc.ibrance', 'indication': 'IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.', 'raw_biomarkers': 'HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Ibrance (palbociclib), fulvestrant'}}, {'id': 'hc:54', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 145, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 1, 'type': 'CategoricalVariant', 'name': 'ER positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}, {'id': 3, 'type': 'CategoricalVariant', 'name': 'PR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 28, 'membershipOperator': 'AND', 'therapies': [30, 31]}, 'therapies': [{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primary_coding_id': 'ncit:C1379', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primary_coding_id': 'ncit:C49176', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.ibrance:1', 'document_id': 'doc:hc.ibrance', 'indication': 'IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.', 'raw_biomarkers': 'HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Ibrance (palbociclib), fulvestrant'}}, {'id': 'hc:55', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.iclusig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iclusig (ponatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Takeda Pharmaceuticals U.S.A., Inc. Iclusig (ponatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078669.PDF. Revised February. Accessed June 2025.', 'company': 'Takeda Pharmaceuticals U.S.A., Inc.', 'drug_name_brand': 'Iclusig', 'drug_name_generic': 'ponatinib', 'first_published': '2015-03-31', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-02-24', 'url': 'https://pdf.hres.ca/dpd_pm/00078669.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92168', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 363, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 32, 'type': 'CategoricalVariant', 'name': 'ABL1 p.T315I', 'genes': [0], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '9'}, {'name': 'start_position', 'value': 133748283}, {'name': 'end_position', 'value': 133748283}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.944C>T'}, {'name': 'protein_change', 'value': 'p.T315I'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 5}, {'name': 'rsid', 'value': 'rs121913459'}, {'name': 'hgvsg', 'value': '9:g.133748283C>T'}, {'name': 'hgvsc', 'value': 'ENST00000318560.5:c.944C>T'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 43, 'conceptType': 'Drug', 'name': 'Ponatinib', 'primary_coding_id': 'ncit:C95777', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 13, 'conceptType': 'Disease', 'name': 'Chronic Myelogenous Leukemia', 'primary_coding_id': 'oncotree:CML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.iclusig:0', 'document_id': 'doc:hc.iclusig', 'indication': 'ICLUSIG (ponatinib tablets) is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML that is T315I mutation positive or where there is prior TKI resistance or intolerance', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are not appropriate for other tyrosine kinase inhibitor (TKI) therapy, including those with the T315I mutation or prior TKI resistance or intolerance.', 'raw_biomarkers': 'T315I mutation positive', 'raw_cancer_type': 'chronic myeloid leukemia (CML)', 'raw_therapeutics': 'Iclusig (ponatinib)'}}, {'id': 'hc:56', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.iclusig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iclusig (ponatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Takeda Pharmaceuticals U.S.A., Inc. Iclusig (ponatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078669.PDF. Revised February. Accessed June 2025.', 'company': 'Takeda Pharmaceuticals U.S.A., Inc.', 'drug_name_brand': 'Iclusig', 'drug_name_generic': 'ponatinib', 'first_published': '2015-03-31', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-02-24', 'url': 'https://pdf.hres.ca/dpd_pm/00078669.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92168', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 362, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 32, 'type': 'CategoricalVariant', 'name': 'ABL1 p.T315I', 'genes': [0], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '9'}, {'name': 'start_position', 'value': 133748283}, {'name': 'end_position', 'value': 133748283}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.944C>T'}, {'name': 'protein_change', 'value': 'p.T315I'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 5}, {'name': 'rsid', 'value': 'rs121913459'}, {'name': 'hgvsg', 'value': '9:g.133748283C>T'}, {'name': 'hgvsc', 'value': 'ENST00000318560.5:c.944C>T'}, {'name': '_present', 'value': True}]}, {'id': 12, 'type': 'CategoricalVariant', 'name': 'BCR::ABL1', 'genes': [6, 0], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 43, 'conceptType': 'Drug', 'name': 'Ponatinib', 'primary_coding_id': 'ncit:C95777', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 0, 'conceptType': 'Disease', 'name': 'Acute Lymphoid Leukemia', 'primary_coding_id': 'oncotree:ALL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.iclusig:1', 'document_id': 'doc:hc.iclusig', 'indication': 'ICLUSIG (ponatinib tablets) is indicated for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including Ph+ ALL that is T315I mutation positive or where there is prior TKI resistance or intolerance', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are not appropriate for other tyrosine kinase inhibitor (TKI) therapy, including those with the T315I mutation or prior TKI resistance or intolerance.', 'raw_biomarkers': 'Philadelphia chromosome positive, T315I mutation positive', 'raw_cancer_type': 'acute lymphoblastic leukemia (Ph+ ALL)', 'raw_therapeutics': 'Iclusig (ponatinib)'}}, {'id': 'hc:57', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Imfinzi (durvalumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080178.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-11-03', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-10', 'url': 'https://pdf.hres.ca/dpd_pm/00080178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 585, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 34, 'type': 'CategoricalVariant', 'name': 'Wild type ALK', 'genes': [2], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}, {'id': 35, 'type': 'CategoricalVariant', 'name': 'Wild type EGFR', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 117, 'membershipOperator': 'AND', 'therapies': [37, 44, 45]}, 'therapies': [{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primary_coding_id': 'ncit:C1282', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primary_coding_id': 'ncit:C103194', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 45, 'conceptType': 'Drug', 'name': 'Tremelimumab', 'primary_coding_id': 'ncit:C49085', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.imfinzi:0', 'document_id': 'doc:hc.imfinzi', 'indication': 'IMFINZI (durvalumab) in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved durvalumab in combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.', 'raw_biomarkers': 'no sensitizing EGFR mutations or ALK genomic aberrations', 'raw_cancer_type': 'metastatic non-small cell lung cancer', 'raw_therapeutics': 'Imfinzi (durvalumab), tremelimumab, platinum-based chemotherapy'}}, {'id': 'hc:58', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Imfinzi (durvalumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080178.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-11-03', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-10', 'url': 'https://pdf.hres.ca/dpd_pm/00080178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 109, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 36, 'type': 'CategoricalVariant', 'name': 'dMMR', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'status', 'value': 'Deficient'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 25, 'membershipOperator': 'AND', 'therapies': [37, 44, 35]}, 'therapies': [{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primary_coding_id': 'ncit:C1282', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primary_coding_id': 'ncit:C103194', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primary_coding_id': 'ncit:C1411', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 18, 'conceptType': 'Disease', 'name': 'Endometrial Carcinoma', 'primary_coding_id': 'oncotree:UCEC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.imfinzi:1', 'document_id': 'doc:hc.imfinzi', 'indication': 'Imfinzi (durvalumab) in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.', 'raw_biomarkers': 'mismatch repair deficient (dMMR)', 'raw_cancer_type': 'primary advanced or recurrent endometrial cancer', 'raw_therapeutics': 'Imfinzi (durvalumab), carboplatin, paclitaxel'}}, {'id': 'hc:59', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.iressa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iressa (gefitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Iressa', 'drug_name_generic': 'gefitinib', 'first_published': '2003-12-17', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00060650.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 147, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 10, 'type': 'CategoricalVariant', 'name': 'EGFR Exon 19 (Deletion)', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': 19}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 33, 'conceptType': 'Drug', 'name': 'Gefitinib', 'primary_coding_id': 'ncit:C1855', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.iressa:0', 'document_id': 'doc:hc.iressa', 'indication': 'IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ', 'raw_biomarkers': 'activating mutations of EGFR', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Iressa (gefitinib)'}}, {'id': 'hc:60', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.iressa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iressa (gefitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Iressa', 'drug_name_generic': 'gefitinib', 'first_published': '2003-12-17', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00060650.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 148, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 9, 'type': 'CategoricalVariant', 'name': 'EGFR p.L858R', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 21}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}, {'name': 'hgvsc', 'value': 'ENST00000275493.2:c.2573T>G'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 33, 'conceptType': 'Drug', 'name': 'Gefitinib', 'primary_coding_id': 'ncit:C1855', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.iressa:0', 'document_id': 'doc:hc.iressa', 'indication': 'IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ', 'raw_biomarkers': 'activating mutations of EGFR', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Iressa (gefitinib)'}}, {'id': 'hc:61', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.iressa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iressa (gefitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Iressa', 'drug_name_generic': 'gefitinib', 'first_published': '2003-12-17', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00060650.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 559, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 19, 'type': 'CategoricalVariant', 'name': 'EGFR oncogenic variants', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 33, 'conceptType': 'Drug', 'name': 'Gefitinib', 'primary_coding_id': 'ncit:C1855', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.iressa:0', 'document_id': 'doc:hc.iressa', 'indication': 'IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ', 'raw_biomarkers': 'activating mutations of EGFR', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Iressa (gefitinib)'}}, {'id': 'hc:62', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.itovebi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Itovebi (inavolisib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Itovebi', 'drug_name_generic': 'inavolisib', 'first_published': '2025-02-14', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-02-14', 'url': 'https://pdf.hres.ca/dpd_pm/00078611.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 510, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 1, 'type': 'CategoricalVariant', 'name': 'ER positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}, {'id': 59, 'type': 'CategoricalVariant', 'name': 'PIK3CA somatic variants', 'genes': [41], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': False}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 95, 'membershipOperator': 'AND', 'therapies': [30, 144, 31]}, 'therapies': [{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primary_coding_id': 'ncit:C1379', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 144, 'conceptType': 'Drug', 'name': 'Inavolisib', 'primary_coding_id': 'ncit:C132166', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primary_coding_id': 'ncit:C49176', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.itovebi:0', 'document_id': 'doc:hc.itovebi', 'indication': 'ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.', 'raw_biomarkers': 'PIK3CA-mutated, HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Itovebi (inavolisib), palbociclib, fulvestrant'}}, {'id': 'hc:63', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.itovebi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Itovebi (inavolisib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Itovebi', 'drug_name_generic': 'inavolisib', 'first_published': '2025-02-14', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-02-14', 'url': 'https://pdf.hres.ca/dpd_pm/00078611.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 511, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}, {'id': 3, 'type': 'CategoricalVariant', 'name': 'PR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 59, 'type': 'CategoricalVariant', 'name': 'PIK3CA somatic variants', 'genes': [41], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': False}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 95, 'membershipOperator': 'AND', 'therapies': [30, 144, 31]}, 'therapies': [{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primary_coding_id': 'ncit:C1379', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 144, 'conceptType': 'Drug', 'name': 'Inavolisib', 'primary_coding_id': 'ncit:C132166', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primary_coding_id': 'ncit:C49176', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.itovebi:0', 'document_id': 'doc:hc.itovebi', 'indication': 'ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.', 'raw_biomarkers': 'PIK3CA-mutated, HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Itovebi (inavolisib), palbociclib, fulvestrant'}}, {'id': 'hc:63', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.itovebi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Itovebi (inavolisib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Itovebi', 'drug_name_generic': 'inavolisib', 'first_published': '2025-02-14', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-02-14', 'url': 'https://pdf.hres.ca/dpd_pm/00078611.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 512, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 1, 'type': 'CategoricalVariant', 'name': 'ER positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}, {'id': 3, 'type': 'CategoricalVariant', 'name': 'PR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 59, 'type': 'CategoricalVariant', 'name': 'PIK3CA somatic variants', 'genes': [41], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': False}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 95, 'membershipOperator': 'AND', 'therapies': [30, 144, 31]}, 'therapies': [{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primary_coding_id': 'ncit:C1379', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 144, 'conceptType': 'Drug', 'name': 'Inavolisib', 'primary_coding_id': 'ncit:C132166', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primary_coding_id': 'ncit:C49176', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.itovebi:0', 'document_id': 'doc:hc.itovebi', 'indication': 'ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.', 'raw_biomarkers': 'PIK3CA-mutated, HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Itovebi (inavolisib), palbociclib, fulvestrant'}}, {'id': 'hc:64', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.jemperli', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Jemperli (dostarlimab) [product monograph]. HC.', 'aliases': [], 'citation': 'GlaxoSmithKline Inc. Jemperli (dostarlimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080289.PDF. Published April 2025. Accessed June 2025.', 'company': 'GlaxoSmithKline Inc.', 'drug_name_brand': 'Jemperli', 'drug_name_generic': 'dostarlimab', 'first_published': '2025-04-06', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-16', 'url': 'https://pdf.hres.ca/dpd_pm/00080289.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101252', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 102, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 36, 'type': 'CategoricalVariant', 'name': 'dMMR', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'status', 'value': 'Deficient'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 47, 'conceptType': 'Drug', 'name': 'Dostarlimab', 'primary_coding_id': 'ncit:C126799', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 18, 'conceptType': 'Disease', 'name': 'Endometrial Carcinoma', 'primary_coding_id': 'oncotree:UCEC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.jemperli:0', 'document_id': 'doc:hc.jemperli', 'indication': 'JEMPERLI (dostarlimab for injection) is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dostarlimab as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.', 'raw_biomarkers': 'mismatch repair deficient (dMMR), microsatellite instability-high (MSI-H)', 'raw_cancer_type': 'recurrent or advanced endometrial cancer', 'raw_therapeutics': 'Jemperli (dostarlimab)'}}, {'id': 'hc:65', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.jemperli', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Jemperli (dostarlimab) [product monograph]. HC.', 'aliases': [], 'citation': 'GlaxoSmithKline Inc. Jemperli (dostarlimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080289.PDF. Published April 2025. Accessed June 2025.', 'company': 'GlaxoSmithKline Inc.', 'drug_name_brand': 'Jemperli', 'drug_name_generic': 'dostarlimab', 'first_published': '2025-04-06', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-16', 'url': 'https://pdf.hres.ca/dpd_pm/00080289.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101252', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 587, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 38, 'type': 'CategoricalVariant', 'name': 'MSI-H', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 47, 'conceptType': 'Drug', 'name': 'Dostarlimab', 'primary_coding_id': 'ncit:C126799', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 18, 'conceptType': 'Disease', 'name': 'Endometrial Carcinoma', 'primary_coding_id': 'oncotree:UCEC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.jemperli:0', 'document_id': 'doc:hc.jemperli', 'indication': 'JEMPERLI (dostarlimab for injection) is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dostarlimab as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.', 'raw_biomarkers': 'mismatch repair deficient (dMMR), microsatellite instability-high (MSI-H)', 'raw_cancer_type': 'recurrent or advanced endometrial cancer', 'raw_therapeutics': 'Jemperli (dostarlimab)'}}, {'id': 'hc:66', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kadcyla', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kadcyla (ado-trastuzumab emtansine) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Kadcyla (ado-trastuzumab emtansine) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067729.PDF. Revised October 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Kadcyla', 'drug_name_generic': 'ado-trastuzumab emtansine', 'first_published': '2013-09-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2022-10-13', 'url': 'https://pdf.hres.ca/dpd_pm/00067729.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89698', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 20, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 52, 'conceptType': 'Drug', 'name': 'Trastuzumab emtansine', 'primary_coding_id': 'ncit:C82492', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kadcyla:0', 'document_id': 'doc:hc.kadcyla', 'indication': 'KADCYLA (trastuzumab emtansine for injection) monotherapy is indicated for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Kadcyla (trastuzumab emtansine)'}}, {'id': 'hc:67', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kadcyla', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kadcyla (ado-trastuzumab emtansine) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Kadcyla (ado-trastuzumab emtansine) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067729.PDF. Revised October 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Kadcyla', 'drug_name_generic': 'ado-trastuzumab emtansine', 'first_published': '2013-09-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2022-10-13', 'url': 'https://pdf.hres.ca/dpd_pm/00067729.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89698', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 20, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 52, 'conceptType': 'Drug', 'name': 'Trastuzumab emtansine', 'primary_coding_id': 'ncit:C82492', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kadcyla:1', 'document_id': 'doc:hc.kadcyla', 'indication': 'KADCYLA monotherapy indicated for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'early breast cancer', 'raw_therapeutics': 'Kadcyla (trastuzumab emtansine)'}}, {'id': 'hc:68', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:0', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.', 'raw_biomarkers': 'BRAF V600 mutation', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}, 'proposition': None}, {'id': 'hc:69', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 318, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 33, 'type': 'CategoricalVariant', 'name': 'PD-L1 >= 1%', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': 0.01}, {'name': '_present', 'value': True}]}, {'id': 34, 'type': 'CategoricalVariant', 'name': 'Wild type ALK', 'genes': [2], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}, {'id': 35, 'type': 'CategoricalVariant', 'name': 'Wild type EGFR', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primary_coding_id': 'ncit:C106432', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:1', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) or stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 [Tumour Proportion Score (TPS)  1%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab for the first-line treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) or stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 [Tumour Proportion Score (TPS)  1%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.', 'raw_biomarkers': 'PD-L1 (TPS  1%), EGFR genomic tumour aberrations, ALK genomic tumour aberrations', 'raw_cancer_type': 'metastatic non-small cell lung carcinoma (NSCLC)', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'id': 'hc:70', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:2', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with pemetrexed and platinum chemotherapy, is indicated for the treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab in combination with pemetrexed and platinum chemotherapy for the treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.', 'raw_biomarkers': 'no EGFR or ALK genomic tumour aberrations', 'raw_cancer_type': 'metastatic non-squamous non-small cell lung carcinoma', 'raw_therapeutics': 'Keytruda (pembrolizumab), pemetrexed, platinum chemotherapy'}, 'proposition': None}, {'id': 'hc:71', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:2', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with pemetrexed and platinum chemotherapy, is indicated for the treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab in combination with pemetrexed and platinum chemotherapy for the treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.', 'raw_biomarkers': 'no EGFR or ALK genomic tumour aberrations', 'raw_cancer_type': 'metastatic non-squamous non-small cell lung carcinoma', 'raw_therapeutics': 'Keytruda (pembrolizumab), pemetrexed, platinum chemotherapy'}, 'proposition': None}, {'id': 'hc:72', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 319, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 33, 'type': 'CategoricalVariant', 'name': 'PD-L1 >= 1%', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': 0.01}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primary_coding_id': 'ncit:C106432', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:3', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated Keytruda as monotherapy is indicated for the treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 (TPS  1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab as a monotherapy for treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 (TPS  1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy.', 'raw_biomarkers': 'PD-L1 (TPS  1%)', 'raw_cancer_type': 'metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'id': 'hc:73', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 323, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 36, 'type': 'CategoricalVariant', 'name': 'dMMR', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'status', 'value': 'Deficient'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primary_coding_id': 'ncit:C106432', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 15, 'conceptType': 'Disease', 'name': 'Colorectal Adenocarcinoma', 'primary_coding_id': 'oncotree:COADREAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:4', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated, as monotherapy, for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab as a monotherapy for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.', 'raw_biomarkers': 'MSI-H or dMMR', 'raw_cancer_type': 'metastatic colorectal cancer (CRC)', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'id': 'hc:74', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 324, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 38, 'type': 'CategoricalVariant', 'name': 'MSI-H', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primary_coding_id': 'ncit:C106432', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 15, 'conceptType': 'Disease', 'name': 'Colorectal Adenocarcinoma', 'primary_coding_id': 'oncotree:COADREAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:4', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated, as monotherapy, for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab as a monotherapy for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.', 'raw_biomarkers': 'MSI-H or dMMR', 'raw_cancer_type': 'metastatic colorectal cancer (CRC)', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'id': 'hc:75', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 321, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 36, 'type': 'CategoricalVariant', 'name': 'dMMR', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'status', 'value': 'Deficient'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primary_coding_id': 'ncit:C106432', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 5, 'conceptType': 'Disease', 'name': 'Any solid tumor', 'primary_coding_id': 'ncit:C132146', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:5', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': '', 'raw_biomarkers': 'MSI-H or dMMR ', 'raw_cancer_type': 'unresectable or metastatic MSI-H or dMMR solid tumors', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'id': 'hc:76', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 322, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 38, 'type': 'CategoricalVariant', 'name': 'MSI-H', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primary_coding_id': 'ncit:C106432', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 5, 'conceptType': 'Disease', 'name': 'Any solid tumor', 'primary_coding_id': 'ncit:C132146', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:5', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': '', 'raw_biomarkers': 'MSI-H or dMMR ', 'raw_cancer_type': 'unresectable or metastatic MSI-H or dMMR solid tumors', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'id': 'hc:77', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:6', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab in combination with lenvatinib for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.', 'raw_biomarkers': 'not MSI-H or dMMR', 'raw_cancer_type': 'advanced endometrial carcinoma', 'raw_therapeutics': 'Keytruda (pembrolizumab), lenvatinib'}, 'proposition': None}, {'id': 'hc:78', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 320, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 42, 'type': 'CategoricalVariant', 'name': 'PD-L1 (CPS) >= 1', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': 1}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primary_coding_id': 'ncit:C106432', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 25, 'conceptType': 'Disease', 'name': 'Head and Neck Squamous Cell Carcinoma', 'primary_coding_id': 'oncotree:HNSC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:7', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression (Combined Positive Score [CPS]  1) as determined by a validated test.', 'initial_approval_date': '', 'initial_approval_url': ' ', 'description': 'Health Canada approved pembrolizumab for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression (Combined Positive Score [CPS]  1) as determined by a validated test.', 'raw_biomarkers': 'PD-L1 (CPS  1)', 'raw_cancer_type': ' metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC)', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 325, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 42, 'type': 'CategoricalVariant', 'name': 'PD-L1 (CPS) >= 1', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': 1}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 53, 'membershipOperator': 'AND', 'therapies': [39, 48, 25, 29]}, 'therapies': [{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primary_coding_id': 'ncit:C376', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primary_coding_id': 'ncit:C106432', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primary_coding_id': 'ncit:C1647', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primary_coding_id': 'ncit:C505', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 2, 'conceptType': 'Disease', 'name': 'Adenocarcinoma of the Gastroesophageal Junction', 'primary_coding_id': 'oncotree:GEJ', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:8', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy,is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumours express PD-L1 (Combined Positive Score [CPS] 1) as determined by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumours express PD-L1 (Combined Positive Score [CPS] 1) as determined by a validated test.', 'raw_biomarkers': 'HER2-positive, PD-L1 (CPS  1)', 'raw_cancer_type': ' locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma', 'raw_therapeutics': 'Keytruda (pembrolizumab), trastuzumab, fluoropyrimidine, platinum-containing chemotherapy'}}, {'id': 'hc:77', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 327, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 55, 'membershipOperator': 'AND', 'therapies': [39, 48, 29]}, 'therapies': [{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primary_coding_id': 'ncit:C376', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primary_coding_id': 'ncit:C106432', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primary_coding_id': 'ncit:C505', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 2, 'conceptType': 'Disease', 'name': 'Adenocarcinoma of the Gastroesophageal Junction', 'primary_coding_id': 'oncotree:GEJ', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:9', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.', 'raw_biomarkers': 'HER2-negative', 'raw_cancer_type': ' locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.', 'raw_therapeutics': 'Keytruda (pembrolizumab), fluoropyrimidine, platinum-containing chemotherapy'}}, {'id': 'hc:77', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 346, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 41, 'type': 'CategoricalVariant', 'name': 'PD-L1 (CPS) >= 10', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': 10}, {'name': '_present', 'value': True}]}, {'id': 43, 'type': 'CategoricalVariant', 'name': 'ER negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}, {'id': 44, 'type': 'CategoricalVariant', 'name': 'PR negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 63, 'membershipOperator': 'AND', 'therapies': [35, 48]}, 'therapies': [{'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primary_coding_id': 'ncit:C1411', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primary_coding_id': 'ncit:C106432', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:10', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with chemotherapy, is indicated for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (Combined Positive Score [CPS]  10) as determined by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab, in combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (Combined Positive Score [CPS]  10) as determined by a validated test.', 'raw_biomarkers': 'PD-L1 (CPS) >= 10', 'raw_cancer_type': 'locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC)', 'raw_therapeutics': 'Keytruda (pembrolizumab), chemotherapy'}}, {'id': 'hc:77', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:11', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS  1) as determined by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab, in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS  1) as determined by a validated test.', 'raw_biomarkers': 'PD-L1 (CPS  1)', 'raw_cancer_type': 'persistent, recurrent, or metastatic cervical cancer', 'raw_therapeutics': 'Keytruda (pembrolizumab), chemotherapy, bevacizumab'}, 'proposition': None}, {'id': 'hc:78', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 372, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 1, 'type': 'CategoricalVariant', 'name': 'ER positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 77, 'membershipOperator': 'AND', 'therapies': [36, 53]}, 'therapies': [{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primary_coding_id': 'ncit:C1607', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primary_coding_id': 'ncit:C95701', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:0', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), aromatase inhibitor'}}, {'id': 'hc:79', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 373, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}, {'id': 3, 'type': 'CategoricalVariant', 'name': 'PR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 77, 'membershipOperator': 'AND', 'therapies': [36, 53]}, 'therapies': [{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primary_coding_id': 'ncit:C1607', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primary_coding_id': 'ncit:C95701', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:0', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), aromatase inhibitor'}}, {'id': 'hc:80', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 374, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 1, 'type': 'CategoricalVariant', 'name': 'ER positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}, {'id': 3, 'type': 'CategoricalVariant', 'name': 'PR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 77, 'membershipOperator': 'AND', 'therapies': [36, 53]}, 'therapies': [{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primary_coding_id': 'ncit:C1607', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primary_coding_id': 'ncit:C95701', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:0', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), aromatase inhibitor'}}, {'id': 'hc:81', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:0', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), aromatase inhibitor'}, 'proposition': None}, {'id': 'hc:82', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:0', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), aromatase inhibitor'}, 'proposition': None}, {'id': 'hc:83', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:0', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), aromatase inhibitor'}, 'proposition': None}, {'id': 'hc:84', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:1', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with fulvestrant, for the treatment ostmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), fulvestrant'}, 'proposition': None}, {'id': 'hc:85', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:1', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with fulvestrant, for the treatment ostmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), fulvestrant'}, 'proposition': None}, {'id': 'hc:86', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lazcluze', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lazcluze (lazertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Lazcluze (lazertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078792.PDF. Published March 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Lazcluze', 'drug_name_generic': 'lazertinib', 'first_published': '2025-03-06', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-06', 'url': 'https://pdf.hres.ca/dpd_pm/00078792.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 463, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 10, 'type': 'CategoricalVariant', 'name': 'EGFR Exon 19 (Deletion)', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': 19}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 85, 'membershipOperator': 'AND', 'therapies': [139, 108]}, 'therapies': [{'id': 139, 'conceptType': 'Drug', 'name': 'Lazertinib', 'primary_coding_id': 'ncit:C148147', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primary_coding_id': 'ncit:C124993', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lazcluze:0', 'document_id': 'doc:hc.lazcluze', 'indication': 'LAZCLUZE (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Lazcluze (lazertinib), amivantamab'}}, {'id': 'hc:87', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lazcluze', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lazcluze (lazertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Lazcluze (lazertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078792.PDF. Published March 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Lazcluze', 'drug_name_generic': 'lazertinib', 'first_published': '2025-03-06', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-06', 'url': 'https://pdf.hres.ca/dpd_pm/00078792.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 464, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 9, 'type': 'CategoricalVariant', 'name': 'EGFR p.L858R', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 21}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}, {'name': 'hgvsc', 'value': 'ENST00000275493.2:c.2573T>G'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 85, 'membershipOperator': 'AND', 'therapies': [139, 108]}, 'therapies': [{'id': 139, 'conceptType': 'Drug', 'name': 'Lazertinib', 'primary_coding_id': 'ncit:C148147', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primary_coding_id': 'ncit:C124993', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lazcluze:0', 'document_id': 'doc:hc.lazcluze', 'indication': 'LAZCLUZE (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Lazcluze (lazertinib), amivantamab'}}, {'id': 'hc:88', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.libtayo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Libtayo (cemiplimab) [product monograph]. HC.', 'aliases': [], 'citation': 'Regeneron Canada Company. Libtayo (cemiplimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078455.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Regeneron Canada Company', 'drug_name_brand': 'Libtayo', 'drug_name_generic': 'cemiplimab', 'first_published': '2019-04-10', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-01-30', 'url': 'https://pdf.hres.ca/dpd_pm/00078455.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97728', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 618, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 39, 'type': 'CategoricalVariant', 'name': 'PD-L1 >= 50%', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': 0.5}, {'name': '_present', 'value': True}]}, {'id': 34, 'type': 'CategoricalVariant', 'name': 'Wild type ALK', 'genes': [2], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}, {'id': 35, 'type': 'CategoricalVariant', 'name': 'Wild type EGFR', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}, {'id': 46, 'type': 'CategoricalVariant', 'name': 'Wild type ROS1', 'genes': [50], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 55, 'conceptType': 'Drug', 'name': 'Cemiplimab', 'primary_coding_id': 'ncit:C121540', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.libtayo:0', 'document_id': 'doc:hc.libtayo', 'indication': 'LIBTAYO (cemiplimab for injection) is indicated as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  50% of tumour cells (Tumour Proportion Score [TPS]  50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cemiplimab as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  50% of tumour cells (Tumour Proportion Score [TPS]  50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.', 'raw_biomarkers': 'PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] with no EGFR, ALK or ROS1 aberrations', 'raw_cancer_type': 'non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Libtayo (Cemiplimab)'}}, {'id': 'hc:89', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.libtayo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Libtayo (cemiplimab) [product monograph]. HC.', 'aliases': [], 'citation': 'Regeneron Canada Company. Libtayo (cemiplimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078455.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Regeneron Canada Company', 'drug_name_brand': 'Libtayo', 'drug_name_generic': 'cemiplimab', 'first_published': '2019-04-10', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-01-30', 'url': 'https://pdf.hres.ca/dpd_pm/00078455.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97728', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 75, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 34, 'type': 'CategoricalVariant', 'name': 'Wild type ALK', 'genes': [2], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}, {'id': 35, 'type': 'CategoricalVariant', 'name': 'Wild type EGFR', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}, {'id': 46, 'type': 'CategoricalVariant', 'name': 'Wild type ROS1', 'genes': [50], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 13, 'membershipOperator': 'AND', 'therapies': [37, 55, 49]}, 'therapies': [{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primary_coding_id': 'ncit:C1282', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 55, 'conceptType': 'Drug', 'name': 'Cemiplimab', 'primary_coding_id': 'ncit:C121540', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primary_coding_id': 'ncit:C61614', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.libtayo:0', 'document_id': 'doc:hc.libtayo', 'indication': 'LIBTAYO (cemiplimab for injection) is indicated as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  50% of tumour cells (Tumour Proportion Score [TPS]  50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cemiplimab as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  50% of tumour cells (Tumour Proportion Score [TPS]  50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.', 'raw_biomarkers': 'PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] with no EGFR, ALK or ROS1 aberrations', 'raw_cancer_type': 'non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Libtayo (Cemiplimab)'}}, {'id': 'hc:90', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lorbrena', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lorbrena (lorlatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Lorbrena (lorlatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077541.PDF. Revised October 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Lorbrena', 'drug_name_generic': 'lorlatinib', 'first_published': '2019-02-20', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-10-28', 'url': 'https://pdf.hres.ca/dpd_pm/00077541.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97619', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 203, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 8, 'type': 'CategoricalVariant', 'name': 'v::ALK', 'genes': [2], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 56, 'conceptType': 'Drug', 'name': 'Lorlatinib', 'primary_coding_id': 'ncit:C113655', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lorbrena:0', 'document_id': 'doc:hc.', 'indication': 'LORBRENA (lorlatinib) is indicated as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved lorlatinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).', 'raw_biomarkers': 'ALK-positive', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Lorbrena (lorlatinib)'}}, {'id': 'hc:91', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lorbrena', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lorbrena (lorlatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Lorbrena (lorlatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077541.PDF. Revised October 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Lorbrena', 'drug_name_generic': 'lorlatinib', 'first_published': '2019-02-20', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-10-28', 'url': 'https://pdf.hres.ca/dpd_pm/00077541.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97619', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 203, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 8, 'type': 'CategoricalVariant', 'name': 'v::ALK', 'genes': [2], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 56, 'conceptType': 'Drug', 'name': 'Lorlatinib', 'primary_coding_id': 'ncit:C113655', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lorbrena:1', 'document_id': 'doc:hc.lorbrena', 'indication': 'LORBRENA (lorlatinib) is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or aectinib.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved lorlatinib as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or aectinib.', 'raw_biomarkers': 'ALK-positive', 'raw_cancer_type': 'metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Lorbrena (lorlatinib)'}}, {'id': 'hc:92', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lumakras', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lumakras (sotorasib) [product monograph]. HC.', 'aliases': [], 'citation': 'Amgen Canada Inc. Lumakras (sotorasib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078781.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Amgen Canada Inc.', 'drug_name_brand': 'Lumakras', 'drug_name_generic': 'sotorasib', 'first_published': '2021-09-09', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-04', 'url': 'https://pdf.hres.ca/dpd_pm/00078781.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100931', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 411, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 45, 'type': 'CategoricalVariant', 'name': 'KRAS p.G12C', 'genes': [31], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '12'}, {'name': 'start_position', 'value': 25398285}, {'name': 'end_position', 'value': 25398285}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.34G>T'}, {'name': 'protein_change', 'value': 'p.G12C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 2}, {'name': 'rsid', 'value': 'rs121913530'}, {'name': 'hgvsg', 'value': '12:g.25398285C>A'}, {'name': 'hgvsc', 'value': 'ENST00000256078.4:c.34G>T'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 57, 'conceptType': 'Drug', 'name': 'Sotorasib', 'primary_coding_id': 'ncit:C154287', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['RAS inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lumakras:0', 'document_id': 'doc:hc.lumakras', 'indication': 'LUMAKRAS (sotorasib) is indicated for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved sotorasib for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.', 'raw_biomarkers': 'KRAS p.G12C', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Lumakras (sotorasib)'}}, {'id': 'hc:93', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 258, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 48, 'type': 'CategoricalVariant', 'name': 'BRCA1 pathogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:0', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.', 'raw_biomarkers': 'deleterious or suspected deleterious gBRCAm, HER2-negative', 'raw_cancer_type': 'high risk early breast cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:94', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 259, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 50, 'type': 'CategoricalVariant', 'name': 'BRCA2 pathogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:0', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.', 'raw_biomarkers': 'deleterious or suspected deleterious gBRCAm, HER2-negative', 'raw_cancer_type': 'high risk early breast cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:95', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 258, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 48, 'type': 'CategoricalVariant', 'name': 'BRCA1 pathogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:1', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy.', 'raw_biomarkers': 'deleterious or suspected deleterious gBRCAm, HER2-negative', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:96', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 259, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 50, 'type': 'CategoricalVariant', 'name': 'BRCA2 pathogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:1', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy.', 'raw_biomarkers': 'deleterious or suspected deleterious gBRCAm, HER2-negative', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:97', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 231, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 47, 'type': 'CategoricalVariant', 'name': 'BRCA1 oncogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 51, 'conceptType': 'Disease', 'name': 'Ovarian Epithelial Tumor', 'primary_coding_id': 'oncotree:OVT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:2', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.', 'raw_biomarkers': 'BRCA-mutated', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:98', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 232, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 48, 'type': 'CategoricalVariant', 'name': 'BRCA1 pathogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 51, 'conceptType': 'Disease', 'name': 'Ovarian Epithelial Tumor', 'primary_coding_id': 'oncotree:OVT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:2', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.', 'raw_biomarkers': 'BRCA-mutated', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:99', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 233, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 49, 'type': 'CategoricalVariant', 'name': 'BRCA2 oncogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 51, 'conceptType': 'Disease', 'name': 'Ovarian Epithelial Tumor', 'primary_coding_id': 'oncotree:OVT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:2', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.', 'raw_biomarkers': 'BRCA-mutated', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:100', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 234, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 50, 'type': 'CategoricalVariant', 'name': 'BRCA2 pathogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 51, 'conceptType': 'Disease', 'name': 'Ovarian Epithelial Tumor', 'primary_coding_id': 'oncotree:OVT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:2', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.', 'raw_biomarkers': 'BRCA-mutated', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:101', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 235, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 47, 'type': 'CategoricalVariant', 'name': 'BRCA1 oncogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 27, 'conceptType': 'Disease', 'name': 'High-Grade Serous Fallopian Tube Cancer', 'primary_coding_id': 'oncotree:HGSFT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:2', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.', 'raw_biomarkers': 'BRCA-mutated', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:102', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 236, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 48, 'type': 'CategoricalVariant', 'name': 'BRCA1 pathogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 27, 'conceptType': 'Disease', 'name': 'High-Grade Serous Fallopian Tube Cancer', 'primary_coding_id': 'oncotree:HGSFT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:2', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.', 'raw_biomarkers': 'BRCA-mutated', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:103', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 237, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 49, 'type': 'CategoricalVariant', 'name': 'BRCA2 oncogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 27, 'conceptType': 'Disease', 'name': 'High-Grade Serous Fallopian Tube Cancer', 'primary_coding_id': 'oncotree:HGSFT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:2', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.', 'raw_biomarkers': 'BRCA-mutated', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:104', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 238, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 50, 'type': 'CategoricalVariant', 'name': 'BRCA2 pathogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 27, 'conceptType': 'Disease', 'name': 'High-Grade Serous Fallopian Tube Cancer', 'primary_coding_id': 'oncotree:HGSFT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:2', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.', 'raw_biomarkers': 'BRCA-mutated', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:105', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 239, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 47, 'type': 'CategoricalVariant', 'name': 'BRCA1 oncogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 54, 'conceptType': 'Disease', 'name': 'Peritoneal Serous Carcinoma', 'primary_coding_id': 'oncotree:PSEC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:2', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.', 'raw_biomarkers': 'BRCA-mutated', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:106', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 240, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 48, 'type': 'CategoricalVariant', 'name': 'BRCA1 pathogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 54, 'conceptType': 'Disease', 'name': 'Peritoneal Serous Carcinoma', 'primary_coding_id': 'oncotree:PSEC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:2', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.', 'raw_biomarkers': 'BRCA-mutated', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:107', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 241, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 49, 'type': 'CategoricalVariant', 'name': 'BRCA2 oncogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 54, 'conceptType': 'Disease', 'name': 'Peritoneal Serous Carcinoma', 'primary_coding_id': 'oncotree:PSEC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:2', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.', 'raw_biomarkers': 'BRCA-mutated', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:108', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 242, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 50, 'type': 'CategoricalVariant', 'name': 'BRCA2 pathogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 54, 'conceptType': 'Disease', 'name': 'Peritoneal Serous Carcinoma', 'primary_coding_id': 'oncotree:PSEC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:2', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.', 'raw_biomarkers': 'BRCA-mutated', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:109', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 243, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 47, 'type': 'CategoricalVariant', 'name': 'BRCA1 oncogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 43, 'membershipOperator': 'AND', 'therapies': [11, 46]}, 'therapies': [{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primary_coding_id': 'ncit:C2039', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 51, 'conceptType': 'Disease', 'name': 'Ovarian Epithelial Tumor', 'primary_coding_id': 'oncotree:OVT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:3', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.', 'raw_biomarkers': 'HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib), bevacizumab'}}, {'id': 'hc:110', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 244, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 48, 'type': 'CategoricalVariant', 'name': 'BRCA1 pathogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 43, 'membershipOperator': 'AND', 'therapies': [11, 46]}, 'therapies': [{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primary_coding_id': 'ncit:C2039', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 51, 'conceptType': 'Disease', 'name': 'Ovarian Epithelial Tumor', 'primary_coding_id': 'oncotree:OVT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:3', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.', 'raw_biomarkers': 'HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib), bevacizumab'}}, {'id': 'hc:111', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 245, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 49, 'type': 'CategoricalVariant', 'name': 'BRCA2 oncogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 43, 'membershipOperator': 'AND', 'therapies': [11, 46]}, 'therapies': [{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primary_coding_id': 'ncit:C2039', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 51, 'conceptType': 'Disease', 'name': 'Ovarian Epithelial Tumor', 'primary_coding_id': 'oncotree:OVT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:3', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.', 'raw_biomarkers': 'HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib), bevacizumab'}}, {'id': 'hc:112', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 246, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 50, 'type': 'CategoricalVariant', 'name': 'BRCA2 pathogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 43, 'membershipOperator': 'AND', 'therapies': [11, 46]}, 'therapies': [{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primary_coding_id': 'ncit:C2039', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 51, 'conceptType': 'Disease', 'name': 'Ovarian Epithelial Tumor', 'primary_coding_id': 'oncotree:OVT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:3', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.', 'raw_biomarkers': 'HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib), bevacizumab'}}, {'id': 'hc:113', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 248, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 47, 'type': 'CategoricalVariant', 'name': 'BRCA1 oncogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 43, 'membershipOperator': 'AND', 'therapies': [11, 46]}, 'therapies': [{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primary_coding_id': 'ncit:C2039', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 27, 'conceptType': 'Disease', 'name': 'High-Grade Serous Fallopian Tube Cancer', 'primary_coding_id': 'oncotree:HGSFT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:3', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.', 'raw_biomarkers': 'HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib), bevacizumab'}}, {'id': 'hc:114', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 249, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 48, 'type': 'CategoricalVariant', 'name': 'BRCA1 pathogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 43, 'membershipOperator': 'AND', 'therapies': [11, 46]}, 'therapies': [{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primary_coding_id': 'ncit:C2039', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 27, 'conceptType': 'Disease', 'name': 'High-Grade Serous Fallopian Tube Cancer', 'primary_coding_id': 'oncotree:HGSFT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:3', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.', 'raw_biomarkers': 'HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib), bevacizumab'}}, {'id': 'hc:115', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 250, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 49, 'type': 'CategoricalVariant', 'name': 'BRCA2 oncogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 43, 'membershipOperator': 'AND', 'therapies': [11, 46]}, 'therapies': [{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primary_coding_id': 'ncit:C2039', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 27, 'conceptType': 'Disease', 'name': 'High-Grade Serous Fallopian Tube Cancer', 'primary_coding_id': 'oncotree:HGSFT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:3', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.', 'raw_biomarkers': 'HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib), bevacizumab'}}, {'id': 'hc:116', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 251, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 50, 'type': 'CategoricalVariant', 'name': 'BRCA2 pathogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 43, 'membershipOperator': 'AND', 'therapies': [11, 46]}, 'therapies': [{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primary_coding_id': 'ncit:C2039', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 27, 'conceptType': 'Disease', 'name': 'High-Grade Serous Fallopian Tube Cancer', 'primary_coding_id': 'oncotree:HGSFT', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:3', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.', 'raw_biomarkers': 'HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib), bevacizumab'}}, {'id': 'hc:117', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 253, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 47, 'type': 'CategoricalVariant', 'name': 'BRCA1 oncogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 43, 'membershipOperator': 'AND', 'therapies': [11, 46]}, 'therapies': [{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primary_coding_id': 'ncit:C2039', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 54, 'conceptType': 'Disease', 'name': 'Peritoneal Serous Carcinoma', 'primary_coding_id': 'oncotree:PSEC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:3', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.', 'raw_biomarkers': 'HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib), bevacizumab'}}, {'id': 'hc:118', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 254, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 48, 'type': 'CategoricalVariant', 'name': 'BRCA1 pathogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 43, 'membershipOperator': 'AND', 'therapies': [11, 46]}, 'therapies': [{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primary_coding_id': 'ncit:C2039', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 54, 'conceptType': 'Disease', 'name': 'Peritoneal Serous Carcinoma', 'primary_coding_id': 'oncotree:PSEC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:3', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.', 'raw_biomarkers': 'HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib), bevacizumab'}}, {'id': 'hc:119', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 255, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 49, 'type': 'CategoricalVariant', 'name': 'BRCA2 oncogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 43, 'membershipOperator': 'AND', 'therapies': [11, 46]}, 'therapies': [{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primary_coding_id': 'ncit:C2039', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 54, 'conceptType': 'Disease', 'name': 'Peritoneal Serous Carcinoma', 'primary_coding_id': 'oncotree:PSEC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:3', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.', 'raw_biomarkers': 'HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib), bevacizumab'}}, {'id': 'hc:120', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 256, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 50, 'type': 'CategoricalVariant', 'name': 'BRCA2 pathogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 43, 'membershipOperator': 'AND', 'therapies': [11, 46]}, 'therapies': [{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primary_coding_id': 'ncit:C2039', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 54, 'conceptType': 'Disease', 'name': 'Peritoneal Serous Carcinoma', 'primary_coding_id': 'oncotree:PSEC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:3', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.', 'raw_biomarkers': 'HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability', 'raw_cancer_type': 'advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer', 'raw_therapeutics': 'Lynparza (olaparib), bevacizumab'}}, {'id': 'hc:121', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 260, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 48, 'type': 'CategoricalVariant', 'name': 'BRCA1 pathogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 52, 'conceptType': 'Disease', 'name': 'Pancreatic Adenocarcinoma', 'primary_coding_id': 'oncotree:PAAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:4', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy.', 'raw_biomarkers': 'deleterious or suspected deleterious germline BRCA-mutated (gBRCAm)', 'raw_cancer_type': 'metastatic adenocarcinoma of the pancreas', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:122', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 261, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 50, 'type': 'CategoricalVariant', 'name': 'BRCA2 pathogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 52, 'conceptType': 'Disease', 'name': 'Pancreatic Adenocarcinoma', 'primary_coding_id': 'oncotree:PAAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:4', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy.', 'raw_biomarkers': 'deleterious or suspected deleterious germline BRCA-mutated (gBRCAm)', 'raw_cancer_type': 'metastatic adenocarcinoma of the pancreas', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:123', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 263, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 47, 'type': 'CategoricalVariant', 'name': 'BRCA1 oncogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:5', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.', 'raw_biomarkers': 'deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation', 'raw_cancer_type': ' metastatic castrationresistant Prostate Cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:124', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 264, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 48, 'type': 'CategoricalVariant', 'name': 'BRCA1 pathogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:5', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.', 'raw_biomarkers': 'deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation', 'raw_cancer_type': ' metastatic castrationresistant Prostate Cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:125', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 265, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 49, 'type': 'CategoricalVariant', 'name': 'BRCA2 oncogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:5', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.', 'raw_biomarkers': 'deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation', 'raw_cancer_type': ' metastatic castrationresistant Prostate Cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:126', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 266, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 50, 'type': 'CategoricalVariant', 'name': 'BRCA2 pathogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:5', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.', 'raw_biomarkers': 'deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation', 'raw_cancer_type': ' metastatic castrationresistant Prostate Cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:127', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 267, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 104, 'type': 'CategoricalVariant', 'name': 'ATM pathogenic variants', 'genes': [3], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '11'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:5', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.', 'raw_biomarkers': 'deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation', 'raw_cancer_type': ' metastatic castrationresistant Prostate Cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:128', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 268, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 105, 'type': 'CategoricalVariant', 'name': 'ATM oncogenic variants', 'genes': [3], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '11'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:5', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.', 'raw_biomarkers': 'deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutation', 'raw_cancer_type': ' metastatic castrationresistant Prostate Cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:129', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 291, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 47, 'type': 'CategoricalVariant', 'name': 'BRCA1 oncogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 45, 'membershipOperator': 'AND', 'therapies': [7, 46, 8]}, 'therapies': [{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primary_coding_id': 'ncit:C68845', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primary_coding_id': 'ncit:C769', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:6', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.', 'raw_biomarkers': 'germline and/or somatic BRCA mutation', 'raw_cancer_type': 'metastatic castration-resistant prostate cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib), abiraterone, prednisone or prednisolone'}}, {'id': 'hc:130', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 292, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 48, 'type': 'CategoricalVariant', 'name': 'BRCA1 pathogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 45, 'membershipOperator': 'AND', 'therapies': [7, 46, 8]}, 'therapies': [{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primary_coding_id': 'ncit:C68845', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primary_coding_id': 'ncit:C769', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:6', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.', 'raw_biomarkers': 'germline and/or somatic BRCA mutation', 'raw_cancer_type': 'metastatic castration-resistant prostate cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib), abiraterone, prednisone or prednisolone'}}, {'id': 'hc:131', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 293, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 49, 'type': 'CategoricalVariant', 'name': 'BRCA2 oncogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 45, 'membershipOperator': 'AND', 'therapies': [7, 46, 8]}, 'therapies': [{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primary_coding_id': 'ncit:C68845', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primary_coding_id': 'ncit:C769', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:6', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.', 'raw_biomarkers': 'germline and/or somatic BRCA mutation', 'raw_cancer_type': 'metastatic castration-resistant prostate cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib), abiraterone, prednisone or prednisolone'}}, {'id': 'hc:132', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 294, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 50, 'type': 'CategoricalVariant', 'name': 'BRCA2 pathogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 45, 'membershipOperator': 'AND', 'therapies': [7, 46, 8]}, 'therapies': [{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primary_coding_id': 'ncit:C68845', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primary_coding_id': 'ncit:C769', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:6', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.', 'raw_biomarkers': 'germline and/or somatic BRCA mutation', 'raw_cancer_type': 'metastatic castration-resistant prostate cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib), abiraterone, prednisone or prednisolone'}}, {'id': 'hc:133', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 295, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 47, 'type': 'CategoricalVariant', 'name': 'BRCA1 oncogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 46, 'membershipOperator': 'AND', 'therapies': [7, 46, 122]}, 'therapies': [{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primary_coding_id': 'ncit:C68845', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primary_coding_id': 'ncit:C770', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:6', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.', 'raw_biomarkers': 'germline and/or somatic BRCA mutation', 'raw_cancer_type': 'metastatic castration-resistant prostate cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib), abiraterone, prednisone or prednisolone'}}, {'id': 'hc:134', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 296, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 48, 'type': 'CategoricalVariant', 'name': 'BRCA1 pathogenic variants', 'genes': [9], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '17'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 46, 'membershipOperator': 'AND', 'therapies': [7, 46, 122]}, 'therapies': [{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primary_coding_id': 'ncit:C68845', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primary_coding_id': 'ncit:C770', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:6', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.', 'raw_biomarkers': 'germline and/or somatic BRCA mutation', 'raw_cancer_type': 'metastatic castration-resistant prostate cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib), abiraterone, prednisone or prednisolone'}}, {'id': 'hc:135', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 297, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 49, 'type': 'CategoricalVariant', 'name': 'BRCA2 oncogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 46, 'membershipOperator': 'AND', 'therapies': [7, 46, 122]}, 'therapies': [{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primary_coding_id': 'ncit:C68845', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primary_coding_id': 'ncit:C770', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:6', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.', 'raw_biomarkers': 'germline and/or somatic BRCA mutation', 'raw_cancer_type': 'metastatic castration-resistant prostate cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib), abiraterone, prednisone or prednisolone'}}, {'id': 'hc:136', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 298, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 50, 'type': 'CategoricalVariant', 'name': 'BRCA2 pathogenic variants', 'genes': [10], 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_pathogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 46, 'membershipOperator': 'AND', 'therapies': [7, 46, 122]}, 'therapies': [{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primary_coding_id': 'ncit:C68845', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primary_coding_id': 'ncit:C71721', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primary_coding_id': 'ncit:C770', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 55, 'conceptType': 'Disease', 'name': 'Prostate Adenocarcinoma', 'primary_coding_id': 'oncotree:PRAD', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:6', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.', 'raw_biomarkers': 'germline and/or somatic BRCA mutation', 'raw_cancer_type': 'metastatic castration-resistant prostate cancer (mCRPC)', 'raw_therapeutics': 'Lynparza (olaparib), abiraterone, prednisone or prednisolone'}}, {'id': 'hc:137', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.mekinist:0', 'document_id': 'doc:hc.mekinist', 'indication': 'MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.', 'raw_biomarkers': 'BRAF V600E or V600K mutation', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Mekinist (trametinib) monotherapy or dabrafenib'}, 'proposition': None}, {'id': 'hc:138', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.mekinist:0', 'document_id': 'doc:hc.mekinist', 'indication': 'MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.', 'raw_biomarkers': 'BRAF V600E or V600K mutation', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Mekinist (trametinib) monotherapy or dabrafenib'}, 'proposition': None}, {'id': 'hc:160', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 417, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 17, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600K', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1798_1799delinsAA'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primary_coding_id': 'ncit:C77908', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 40, 'conceptType': 'Disease', 'name': 'Melanoma', 'primary_coding_id': 'oncotree:MEL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.mekinist:0', 'document_id': 'doc:hc.mekinist', 'indication': 'MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.', 'raw_biomarkers': 'BRAF V600E or V600K mutation', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Mekinist (trametinib) monotherapy or dabrafenib'}}, {'id': 'hc:161', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 416, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 16, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600E', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1799T>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primary_coding_id': 'ncit:C77908', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 40, 'conceptType': 'Disease', 'name': 'Melanoma', 'primary_coding_id': 'oncotree:MEL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.mekinist:0', 'document_id': 'doc:hc.mekinist', 'indication': 'MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.', 'raw_biomarkers': 'BRAF V600E or V600K mutation', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Mekinist (trametinib) monotherapy or dabrafenib'}}, {'id': 'hc:139', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.mekinist:1', 'document_id': 'doc:hc.mekinist', 'indication': 'MEKINIST (trametinib), in combination with dabrafenib, is indicated for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph nodes, following complete resection.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trametinib in combination with dabrafenib for the adjuvant treatment of patients with BRAF V600E or V600K-mutant melanoma and lymph node involvement after complete resection.', 'raw_biomarkers': 'BRAF V600E or V600K mutation', 'raw_cancer_type': 'melanoma', 'raw_therapeutics': 'Mekinist (trametinib), dabrafenib'}, 'proposition': None}, {'id': 'hc:140', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.mekinist:1', 'document_id': 'doc:hc.mekinist', 'indication': 'MEKINIST (trametinib), in combination with dabrafenib, is indicated for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph nodes, following complete resection.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trametinib in combination with dabrafenib for the adjuvant treatment of patients with BRAF V600E or V600K-mutant melanoma and lymph node involvement after complete resection.', 'raw_biomarkers': 'BRAF V600E or V600K mutation', 'raw_cancer_type': 'melanoma', 'raw_therapeutics': 'Mekinist (trametinib), dabrafenib'}, 'proposition': None}, {'id': 'hc:141', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 91, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 16, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600E', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1799T>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 18, 'membershipOperator': 'AND', 'therapies': [67, 66]}, 'therapies': [{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primary_coding_id': 'ncit:C82386', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primary_coding_id': 'ncit:C77908', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.mekinist:2', 'document_id': 'doc:hc.mekinist', 'indication': 'MEKINIST (trametinib) in combination with dabrafenib is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trametinib in combination with dabrafenib for the treatment of patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC).', 'raw_biomarkers': 'BRAF V600E mutation', 'raw_cancer_type': 'metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Mekinist (trametinib), dabrafenib'}}, {'id': 'hc:142', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 94, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 16, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600E', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1799T>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 18, 'membershipOperator': 'AND', 'therapies': [67, 66]}, 'therapies': [{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primary_coding_id': 'ncit:C82386', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primary_coding_id': 'ncit:C77908', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 35, 'conceptType': 'Disease', 'name': 'Low-Grade Glioma, NOS', 'primary_coding_id': 'oncotree:LGGNOS', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.mekinist:3', 'document_id': 'doc:hc.mekinist', 'indication': 'MEKINIST (trametinib) in combination with dabrafenib is indicated for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trametinib in combination with dabrafenib for the treatment of pediatric patients 1 year of age and older with BRAF V600E-mutant low-grade glioma (LGG) requiring systemic therapy.', 'raw_biomarkers': 'BRAF V600E mutation', 'raw_cancer_type': 'low-grade glioma (LGG)', 'raw_therapeutics': 'Mekinist (trametinib), dabrafenib'}}, {'id': 'hc:143', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': '2013-07-18', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077955.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 660, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 16, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600E', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1799T>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 18, 'membershipOperator': 'AND', 'therapies': [67, 66]}, 'therapies': [{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primary_coding_id': 'ncit:C82386', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primary_coding_id': 'ncit:C77908', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 83, 'conceptType': 'Disease', 'name': 'High-Grade Glioma, NOS', 'primary_coding_id': 'oncotree:HGGNOS', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.mekinist:0', 'document_id': 'doc:hc.mekinist', 'indication': 'MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.', 'raw_biomarkers': 'BRAF V600E or V600K mutation', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Mekinist (trametinib) monotherapy or dabrafenib'}}, {'id': 'hc:144', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.mektovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mektovi (binimetinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Mektovi (binimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060288.PDF. Published March 2021. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Mektovi', 'drug_name_generic': 'binimetinib', 'first_published': '2021-03-02', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-03-02', 'url': 'https://pdf.hres.ca/dpd_pm/00060288.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 41, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 16, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600E', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1799T>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 10, 'membershipOperator': 'AND', 'therapies': [17, 18]}, 'therapies': [{'id': 17, 'conceptType': 'Drug', 'name': 'Binimetinib', 'primary_coding_id': 'ncit:C84865', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primary_coding_id': 'ncit:C98283', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 40, 'conceptType': 'Disease', 'name': 'Melanoma', 'primary_coding_id': 'oncotree:MEL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.mektovi:0', 'document_id': 'doc:hc.', 'indication': 'MEKTOVI (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved binimetinib, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'raw_biomarkers': 'BRAF V600E or V600K', 'raw_cancer_type': 'unresectable or metastatic melanoma ', 'raw_therapeutics': 'Mektovi (binimetinib), encorafenib'}}, {'id': 'hc:145', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.mektovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mektovi (binimetinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Mektovi (binimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060288.PDF. Published March 2021. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Mektovi', 'drug_name_generic': 'binimetinib', 'first_published': '2021-03-02', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-03-02', 'url': 'https://pdf.hres.ca/dpd_pm/00060288.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 42, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 17, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600K', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1798_1799delinsAA'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 10, 'membershipOperator': 'AND', 'therapies': [17, 18]}, 'therapies': [{'id': 17, 'conceptType': 'Drug', 'name': 'Binimetinib', 'primary_coding_id': 'ncit:C84865', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primary_coding_id': 'ncit:C98283', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 40, 'conceptType': 'Disease', 'name': 'Melanoma', 'primary_coding_id': 'oncotree:MEL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.mektovi:0', 'document_id': 'doc:hc.', 'indication': 'MEKTOVI (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved binimetinib, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'raw_biomarkers': 'BRAF V600E or V600K', 'raw_cancer_type': 'unresectable or metastatic melanoma ', 'raw_therapeutics': 'Mektovi (binimetinib), encorafenib'}}, {'id': 'hc:146', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.mylotarg', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mylotarg (gemtuzumab ozogamicin) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Mylotarg (gemtuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00069427.PDF. Revised February 2023. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Mylotarg', 'drug_name_generic': 'gemtuzumab ozogamicin', 'first_published': '2019-11-28', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-02-02', 'url': 'https://pdf.hres.ca/dpd_pm/00069427.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98440', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 628, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 55, 'type': 'CategoricalVariant', 'name': 'CD33 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD33'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 126, 'membershipOperator': 'AND', 'therapies': [63, 68, 69]}, 'therapies': [{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primary_coding_id': 'ncit:C408', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primary_coding_id': 'ncit:C62091', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 69, 'conceptType': 'Drug', 'name': 'Gemtuzumab ozogamicin', 'primary_coding_id': 'ncit:C1806', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD33 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 1, 'conceptType': 'Disease', 'name': 'Acute Myeloid Leukemia', 'primary_coding_id': 'oncotree:AML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.mylotarg:0', 'document_id': 'doc:hc.mylotarg', 'indication': 'Mylotarg (gemtuzumab ozogamicin for injection) is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved gemtuzumab ozogamicin  in combination with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia.', 'raw_biomarkers': 'CD33-positive', 'raw_cancer_type': 'acute myeloid leukeia (AML)', 'raw_therapeutics': 'Mylotarg (gemtuzumab ozogamicin), daunorubicin (DNR), cytarabine (AraC)'}}, {'id': 'hc:147', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.nerlynx', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Nerlynx (neratinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.', 'company': 'Knight Therapeutics Inc.', 'drug_name_brand': 'Nerlynx', 'drug_name_generic': 'neratinib', 'first_published': '2019-07-15', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-07-16', 'url': 'https://pdf.hres.ca/dpd_pm/00062158.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 629, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 1, 'type': 'CategoricalVariant', 'name': 'ER positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 3, 'type': 'CategoricalVariant', 'name': 'PR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 70, 'conceptType': 'Drug', 'name': 'Neratinib', 'primary_coding_id': 'ncit:C49094', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.nerlynx:0', 'document_id': 'doc:hc.nerlynx', 'indication': 'NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.', 'raw_biomarkers': 'HR+, HER2-overexpressed/amplified', 'raw_cancer_type': 'early-stage breast cancer', 'raw_therapeutics': 'Nerlynx (neratinib)'}}, {'id': 'hc:148', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.nerlynx', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Nerlynx (neratinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.', 'company': 'Knight Therapeutics Inc.', 'drug_name_brand': 'Nerlynx', 'drug_name_generic': 'neratinib', 'first_published': '2019-07-15', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-07-16', 'url': 'https://pdf.hres.ca/dpd_pm/00062158.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 630, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 1, 'type': 'CategoricalVariant', 'name': 'ER positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 70, 'conceptType': 'Drug', 'name': 'Neratinib', 'primary_coding_id': 'ncit:C49094', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.nerlynx:0', 'document_id': 'doc:hc.nerlynx', 'indication': 'NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.', 'raw_biomarkers': 'HR+, HER2-overexpressed/amplified', 'raw_cancer_type': 'early-stage breast cancer', 'raw_therapeutics': 'Nerlynx (neratinib)'}}, {'id': 'hc:149', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.nerlynx', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Nerlynx (neratinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.', 'company': 'Knight Therapeutics Inc.', 'drug_name_brand': 'Nerlynx', 'drug_name_generic': 'neratinib', 'first_published': '2019-07-15', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-07-16', 'url': 'https://pdf.hres.ca/dpd_pm/00062158.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 631, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 3, 'type': 'CategoricalVariant', 'name': 'PR positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 70, 'conceptType': 'Drug', 'name': 'Neratinib', 'primary_coding_id': 'ncit:C49094', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.nerlynx:0', 'document_id': 'doc:hc.nerlynx', 'indication': 'NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.', 'raw_biomarkers': 'HR+, HER2-overexpressed/amplified', 'raw_cancer_type': 'early-stage breast cancer', 'raw_therapeutics': 'Nerlynx (neratinib)'}}, {'id': 'hc:149', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.nerlynx', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Nerlynx (neratinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.', 'company': 'Knight Therapeutics Inc.', 'drug_name_brand': 'Nerlynx', 'drug_name_generic': 'neratinib', 'first_published': '2019-07-15', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-07-16', 'url': 'https://pdf.hres.ca/dpd_pm/00062158.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 220, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 41, 'membershipOperator': 'AND', 'therapies': [38, 70]}, 'therapies': [{'id': 38, 'conceptType': 'Drug', 'name': 'Capecitabine', 'primary_coding_id': 'ncit:C1794', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 70, 'conceptType': 'Drug', 'name': 'Neratinib', 'primary_coding_id': 'ncit:C49094', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.nerlynx:1', 'document_id': 'doc:hc.nerlynx', 'indication': 'NERLYNX (neratinib) is indicated in combination with capecitabine for the treatment of patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved neratinib in combination with capecitabine for the treatment of patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.', 'raw_biomarkers': 'HER2-overexpressed/amplified', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Nerlynx (neratinib), capecitabine'}}, {'id': 'hc:150', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.opdivo:0', 'document_id': 'doc:hc.opdivo', 'indication': 'OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nivolumab for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.', 'raw_biomarkers': 'BRAF V600 mutation-positive,', 'raw_cancer_type': ' unresectable or metastatic melanoma', 'raw_therapeutics': 'Opdivo (nivolumab)'}, 'proposition': None}, {'id': 'hc:151', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.opdivo:1', 'document_id': 'doc:hc.opdivo', 'indication': 'OPDIVO, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving OPDIVO.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nivolumab as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving OPDIVO.', 'raw_biomarkers': 'EGFR or ALK genomic tumour aberrations', 'raw_cancer_type': ' locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Opdivo (nivolumab)'}, 'proposition': None}, {'id': 'hc:152', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 171, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 33, 'type': 'CategoricalVariant', 'name': 'PD-L1 >= 1%', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': 0.01}, {'name': '_present', 'value': True}]}, {'id': 34, 'type': 'CategoricalVariant', 'name': 'Wild type ALK', 'genes': [2], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}, {'id': 35, 'type': 'CategoricalVariant', 'name': 'Wild type EGFR', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 29, 'membershipOperator': 'AND', 'therapies': [71, 72]}, 'therapies': [{'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primary_coding_id': 'ncit:C2654', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primary_coding_id': 'ncit:C68814', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.opdivo:2', 'document_id': 'doc:hc.', 'indication': 'OPDIVO (nivolumab) in combination with ipilimumab, is indicated for the treatment of adult patients with metastatic NSCLC, expressing PD-L1  1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nivolumab in combination with ipilimumab, for the treatment of adult patients with metastatic NSCLC, expressing PD-L1  1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.', 'raw_biomarkers': ' PD-L1  1% with no EGFR or ALK genomic tumour aberrations', 'raw_cancer_type': 'metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Opdivo (nivolumab), ipilimumab'}}, {'id': 'hc:153', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.opdivo:3', 'document_id': 'doc:hc.opdivo', 'indication': 'OPDIVO (nivolumab), in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nivolumab in combinatiom with ipilimumab and 2 cycles of platinum-doublet chemotherapy, for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.', 'raw_biomarkers': 'no EGFR or ALK tumour genomic tumour aberrations', 'raw_cancer_type': 'metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Opdivo (nivolumab), ipilimumab, 2 cycles of platinum-doublet chemotherapy'}, 'proposition': None}, {'id': 'hc:154', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.opdivo:3', 'document_id': 'doc:hc.opdivo', 'indication': 'OPDIVO (nivolumab), in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nivolumab in combinatiom with ipilimumab and 2 cycles of platinum-doublet chemotherapy, for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.', 'raw_biomarkers': 'no EGFR or ALK tumour genomic tumour aberrations', 'raw_cancer_type': 'metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Opdivo (nivolumab), ipilimumab, 2 cycles of platinum-doublet chemotherapy'}, 'proposition': None}, {'id': 'hc:155', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.opdivo:3', 'document_id': 'doc:hc.opdivo', 'indication': 'OPDIVO (nivolumab), in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nivolumab in combinatiom with ipilimumab and 2 cycles of platinum-doublet chemotherapy, for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.', 'raw_biomarkers': 'no EGFR or ALK tumour genomic tumour aberrations', 'raw_cancer_type': 'metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Opdivo (nivolumab), ipilimumab, 2 cycles of platinum-doublet chemotherapy'}, 'proposition': None}, {'id': 'hc:156', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.opdivo:4', 'document_id': 'doc:hc.opdivo', 'indication': 'OPDIVO (nivolumab), in combination with ipilimumab, is indicated for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nivolumab, in combination with ipilimumab, for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal caner after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan.', 'raw_biomarkers': 'MSI-H or dMMR', 'raw_cancer_type': 'metastatic colorectal cancer', 'raw_therapeutics': 'Opdivo (nivolumab), ipilimumab'}, 'proposition': None}, {'id': 'hc:157', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.opdivo:4', 'document_id': 'doc:hc.opdivo', 'indication': 'OPDIVO (nivolumab), in combination with ipilimumab, is indicated for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nivolumab, in combination with ipilimumab, for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal caner after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan.', 'raw_biomarkers': 'MSI-H or dMMR', 'raw_cancer_type': 'metastatic colorectal cancer', 'raw_therapeutics': 'Opdivo (nivolumab), ipilimumab'}, 'proposition': None}, {'id': 'hc:158', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.opdivo:5', 'document_id': 'doc:hc.opdivo', 'indication': 'OPDIVO (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with HER2 negative advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with HER2 negative advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.', 'raw_biomarkers': 'HER2-negative', 'raw_cancer_type': 'negative advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma', 'raw_therapeutics': 'Opdivo (nivolumab), fluoropyrimidine-, platinum-containing chemotherapy'}, 'proposition': None}, {'id': 'hc:159', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 642, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 33, 'type': 'CategoricalVariant', 'name': 'PD-L1 >= 1%', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': 0.01}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 29, 'membershipOperator': 'AND', 'therapies': [71, 72]}, 'therapies': [{'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primary_coding_id': 'ncit:C2654', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primary_coding_id': 'ncit:C68814', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 82, 'conceptType': 'Disease', 'name': 'Esophageal Squamous Cell Carcinoma', 'primary_coding_id': 'oncotree:ESCC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.opdivo:6', 'document_id': 'doc:hc.', 'indication': 'OPDIVO (nivolumab), in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nivolumab, in combination with ipilimuab, for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.', 'raw_biomarkers': 'PD-L1  1%', 'raw_cancer_type': 'unresectable or metastatic esophageal squamous cell carcinoma (ESCC)', 'raw_therapeutics': 'Opdivo (nivolumab), ipilimumab'}}, {'id': 'hc:162', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 643, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 33, 'type': 'CategoricalVariant', 'name': 'PD-L1 >= 1%', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': 0.01}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 128, 'membershipOperator': 'AND', 'therapies': [39, 72, 29]}, 'therapies': [{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primary_coding_id': 'ncit:C376', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primary_coding_id': 'ncit:C68814', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primary_coding_id': 'ncit:C505', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 82, 'conceptType': 'Disease', 'name': 'Esophageal Squamous Cell Carcinoma', 'primary_coding_id': 'oncotree:ESCC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.opdivo:7', 'document_id': 'doc:hc.opdivo', 'indication': 'OPDIVO (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nivolumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.', 'raw_biomarkers': 'PD-L1  1%', 'raw_cancer_type': 'unresectable or metastatic esophageal squamous cell carcinoma (ESCC)', 'raw_therapeutics': 'Opdivo (nivolumab), fluoropyrimidine-, platinum-containing chemotherapy'}}, {'id': 'hc:163', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2015-09-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-06-28', 'url': 'https://pdf.hres.ca/dpd_pm/00076152.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 800, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 33, 'type': 'CategoricalVariant', 'name': 'PD-L1 >= 1%', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': 0.01}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 129, 'membershipOperator': 'AND', 'therapies': [72, 28, 29]}, 'therapies': [{'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primary_coding_id': 'ncit:C68814', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 28, 'conceptType': 'Drug', 'name': 'Oxaliplatin', 'primary_coding_id': 'ncit:C1181', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primary_coding_id': 'ncit:C505', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 82, 'conceptType': 'Disease', 'name': 'Esophageal Squamous Cell Carcinoma', 'primary_coding_id': 'oncotree:ESCC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.opdivo:7', 'document_id': 'doc:hc.opdivo', 'indication': 'OPDIVO (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nivolumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression  1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.', 'raw_biomarkers': 'PD-L1  1%', 'raw_cancer_type': 'unresectable or metastatic esophageal squamous cell carcinoma (ESCC)', 'raw_therapeutics': 'Opdivo (nivolumab), fluoropyrimidine-, platinum-containing chemotherapy'}}, {'id': 'hc:164', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.pemazyre', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Pemazyre (pemigatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pemazyre (pemigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062968.PDF. Published September 2021. Accessed June 2025.', 'company': 'Incyte Corporation', 'drug_name_brand': 'Pemazyre', 'drug_name_generic': 'pemigatinib', 'first_published': '2021-09-09', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-09-08', 'url': 'https://pdf.hres.ca/dpd_pm/00062968.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100917', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 348, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 52, 'type': 'CategoricalVariant', 'name': 'FGFR2::v', 'genes': [23], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 133, 'conceptType': 'Drug', 'name': 'Pemigatinib', 'primary_coding_id': 'ncit:C121553', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 11, 'conceptType': 'Disease', 'name': 'Cholangiocarcinoma', 'primary_coding_id': 'oncotree:CHOL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.pemazyre:0', 'document_id': 'doc:hc.pemazyre', 'indication': 'PEMAZYRE (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.', 'raw_biomarkers': 'FGFR2 fusion or rearrangement', 'raw_cancer_type': 'unresectable locally advanced or metastatic cholangiocarcinoma', 'raw_therapeutics': 'Pemazyre (pemigatinib)'}}, {'id': 'hc:165', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.pemazyre', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Pemazyre (pemigatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pemazyre (pemigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062968.PDF. Published September 2021. Accessed June 2025.', 'company': 'Incyte Corporation', 'drug_name_brand': 'Pemazyre', 'drug_name_generic': 'pemigatinib', 'first_published': '2021-09-09', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-09-08', 'url': 'https://pdf.hres.ca/dpd_pm/00062968.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100917', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 349, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 53, 'type': 'CategoricalVariant', 'name': 'FGFR2 rearrangements', 'genes': [23], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': None}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 133, 'conceptType': 'Drug', 'name': 'Pemigatinib', 'primary_coding_id': 'ncit:C121553', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 11, 'conceptType': 'Disease', 'name': 'Cholangiocarcinoma', 'primary_coding_id': 'oncotree:CHOL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.pemazyre:0', 'document_id': 'doc:hc.pemazyre', 'indication': 'PEMAZYRE (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.', 'raw_biomarkers': 'FGFR2 fusion or rearrangement', 'raw_cancer_type': 'unresectable locally advanced or metastatic cholangiocarcinoma', 'raw_therapeutics': 'Pemazyre (pemigatinib)'}}, {'id': 'hc:166', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.perjeta:0', 'document_id': 'doc:hc.perjeta', 'indication': 'PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'early stage breast cancer', 'raw_therapeutics': 'Perjeta (pertuzumab), trastuzumab, chemotherapy'}, 'proposition': None}, {'id': 'hc:167', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': '2013-04-12', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2013-04-12', 'url': 'https://pdf.hres.ca/dpd_pm/00060125.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 351, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 65, 'membershipOperator': 'AND', 'therapies': [24, 75, 25]}, 'therapies': [{'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primary_coding_id': 'ncit:C1526', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primary_coding_id': 'ncit:C38692', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primary_coding_id': 'ncit:C1647', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.perjeta:1', 'document_id': 'doc:hc.perjeta', 'indication': 'PERJETA (pertuzumab) is indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pertuzumab in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Perjeta (pertuzumab), trastuzumab, docetaxel'}}, {'id': 'hc:168', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.phesgo:0', 'document_id': 'doc:hc.', 'indication': 'PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'locally advanced, inflammatory, or early stage breast cancer', 'raw_therapeutics': 'Phesgo (pertuzumab and trastuzumab), chemotherapy'}, 'proposition': None}, {'id': 'hc:169', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.phesgo:1', 'document_id': 'doc:hc.phesgo', 'indication': 'PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer with lymph node positive and/or hormone receptor negative disease.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the adjuvant treatment of patients with HER2-poitive early breast cancer with lymph node positive and/hormone receptor negative disease.', 'raw_biomarkers': 'HR-negative, HER2-positive', 'raw_cancer_type': 'early breast cancer', 'raw_therapeutics': 'Phesgo (pertuzumab and trastuzumab), chemotherapy'}, 'proposition': None}, {'id': 'hc:170', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': '2021-03-01', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2022-01-05', 'url': 'https://pdf.hres.ca/dpd_pm/00064237.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 351, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 65, 'membershipOperator': 'AND', 'therapies': [24, 75, 25]}, 'therapies': [{'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primary_coding_id': 'ncit:C1526', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primary_coding_id': 'ncit:C38692', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primary_coding_id': 'ncit:C1647', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.phesgo:2', 'document_id': 'doc:hc.phesgo', 'indication': 'PHESGO (pertuzumab and trastuzumab), is indicated in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC), who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pertuzumab and trastuzumab in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC), who have not received prior anit-HER2 therapy or chemotherapy for metastatic disease.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Phesgo (pertuzumab and trastuzumab), docetaxel'}}, {'id': 'hc:171', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.piqray', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Piqray (alpelisib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Piqray (alpelisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076641.PDF. Revised August 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Piqray', 'drug_name_generic': 'alpelisib', 'first_published': '2020-03-11', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-08-12', 'url': 'https://pdf.hres.ca/dpd_pm/00076641.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98692', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.piqray:0', 'document_id': 'doc:hc.piqray', 'indication': 'PIQRAY (alpelisib), in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved alpelisib in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.', 'raw_biomarkers': 'PIK3CA-mutated, hormone receptor-positive, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Piqray (alpelisib), fulvestrant'}, 'proposition': None}, {'id': 'hc:172', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.piqray', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Piqray (alpelisib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Piqray (alpelisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076641.PDF. Revised August 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Piqray', 'drug_name_generic': 'alpelisib', 'first_published': '2020-03-11', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-08-12', 'url': 'https://pdf.hres.ca/dpd_pm/00076641.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98692', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.piqray:0', 'document_id': 'doc:hc.piqray', 'indication': 'PIQRAY (alpelisib), in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved alpelisib in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.', 'raw_biomarkers': 'PIK3CA-mutated, hormone receptor-positive, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Piqray (alpelisib), fulvestrant'}, 'proposition': None}, {'id': 'hc:171', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.piqray', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Piqray (alpelisib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Piqray (alpelisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076641.PDF. Revised August 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Piqray', 'drug_name_generic': 'alpelisib', 'first_published': '2020-03-11', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-08-12', 'url': 'https://pdf.hres.ca/dpd_pm/00076641.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98692', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.piqray:0', 'document_id': 'doc:hc.piqray', 'indication': 'PIQRAY (alpelisib), in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved alpelisib in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.', 'raw_biomarkers': 'PIK3CA-mutated, hormone receptor-positive, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Piqray (alpelisib), fulvestrant'}, 'proposition': None}, {'id': 'hc:172', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.retevmo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Retevmo (selpercatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Loxo Oncology Inc.', 'drug_name_brand': 'Retevmo', 'drug_name_generic': 'selpercatinib', 'first_published': '2021-06-11', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00078253.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 407, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 18, 'type': 'CategoricalVariant', 'name': 'v::RET', 'genes': [49], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 78, 'conceptType': 'Drug', 'name': 'Selpercatinib', 'primary_coding_id': 'ncit:C134987', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.retevmo:0', 'document_id': 'doc:hc.retevmo', 'indication': 'RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved selpercatinib as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.', 'raw_biomarkers': 'RET fusion-positive', 'raw_cancer_type': 'metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Retevmo (selpercatinib)'}}, {'id': 'hc:173', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.retevmo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Retevmo (selpercatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Loxo Oncology Inc.', 'drug_name_brand': 'Retevmo', 'drug_name_generic': 'selpercatinib', 'first_published': '2021-06-11', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00078253.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 408, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 152, 'type': 'CategoricalVariant', 'name': 'RET oncogenic variants', 'genes': [49], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '10'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': None}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 78, 'conceptType': 'Drug', 'name': 'Selpercatinib', 'primary_coding_id': 'ncit:C134987', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 38, 'conceptType': 'Disease', 'name': 'Medullary Thyroid Cancer', 'primary_coding_id': 'oncotree:THME', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.retevmo:1', 'document_id': 'doc:hc.retevmo', 'indication': 'RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of RET-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved selpercatinib as monotherapy for the treatment of RET-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.', 'raw_biomarkers': 'RET-mutant', 'raw_cancer_type': 'unresectable advanced or metastatic medullary thyroid cancer (MTC)', 'raw_therapeutics': 'Retevmo (selpercatinib)'}}, {'id': 'hc:174', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.retevmo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Retevmo (selpercatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Loxo Oncology Inc.', 'drug_name_brand': 'Retevmo', 'drug_name_generic': 'selpercatinib', 'first_published': '2021-06-11', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00078253.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 656, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 18, 'type': 'CategoricalVariant', 'name': 'v::RET', 'genes': [49], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 78, 'conceptType': 'Drug', 'name': 'Selpercatinib', 'primary_coding_id': 'ncit:C134987', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 75, 'conceptType': 'Disease', 'name': 'Papillary Thyroid Cancer', 'primary_coding_id': 'oncotree:THPA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.retevmo:2', 'document_id': 'doc:hc.retevmo', 'indication': 'RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved selpercatinib as monotherapy for the treatment of RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.', 'raw_biomarkers': 'RET fusion-positive', 'raw_cancer_type': 'advanced or metastatic differentiated thyroid carcinoma', 'raw_therapeutics': 'Retevmo (selpercatinib)'}}, {'id': 'hc:175', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.revlimid', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Revlimid (lenalidomide) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Revlimid (lenalidomide) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074535.PDF. Published February 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Revlimid', 'drug_name_generic': 'lenalidomide', 'first_published': '2024-02-09', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-02-09', 'url': 'https://pdf.hres.ca/dpd_pm/00074535.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79016', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 202, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 61, 'type': 'CategoricalVariant', 'name': '5q deletion', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number (arm level)'}, {'name': 'chromosome', 'value': '5'}, {'name': 'arm', 'value': 'q'}, {'name': 'direction', 'value': 'Deletion'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 79, 'conceptType': 'Drug', 'name': 'Lenalidomide', 'primary_coding_id': 'ncit:C2668', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Angiogenesis inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 43, 'conceptType': 'Disease', 'name': 'Myelodysplastic Syndromes', 'primary_coding_id': 'oncotree:MDS', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.revlimid:0', 'document_id': 'doc:hc.revlimid', 'indication': 'REVLIMID (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Approval for this indication is based on red blood cell transfusion independence response rates. Overall survival benefit has not been demonstrated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved lenalidomide for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogentic abnormalities.', 'raw_biomarkers': '5q deletion', 'raw_cancer_type': 'transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes', 'raw_therapeutics': 'Revlimid (lenalidomide)'}}, {'id': 'hc:176', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': '2000-03-17', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-06-02', 'url': 'https://pdf.hres.ca/dpd_pm/00071131.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 378, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 54, 'type': 'CategoricalVariant', 'name': 'CD20 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primary_coding_id': 'ncit:C1702', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 76, 'conceptType': 'Disease', 'name': 'Non-Hodgkin Lymphoma', 'primary_coding_id': 'oncotree:NHL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rituxan:0', 'document_id': 'doc:hc.rituxan', 'indication': 'RITUXAN (rituximab for injection) is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkins lymphoma.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved rituximab for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkins lymphoma.', 'raw_biomarkers': 'CD20 positive', 'raw_cancer_type': 'relapsed or refractory low-grade or follicular B-cell non-Hodgkins lymphoma', 'raw_therapeutics': 'RITUXAN (rituximab for injection)'}}, {'id': 'hc:177', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': '2000-03-17', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-06-02', 'url': 'https://pdf.hres.ca/dpd_pm/00071131.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 822, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 54, 'type': 'CategoricalVariant', 'name': 'CD20 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primary_coding_id': 'ncit:C1702', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 20, 'conceptType': 'Disease', 'name': 'Follicular Lymphoma', 'primary_coding_id': 'oncotree:FL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rituxan:0', 'document_id': 'doc:hc.rituxan', 'indication': 'RITUXAN (rituximab for injection) is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkins lymphoma.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved rituximab for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkins lymphoma.', 'raw_biomarkers': 'CD20 positive', 'raw_cancer_type': 'relapsed or refractory low-grade or follicular B-cell non-Hodgkins lymphoma', 'raw_therapeutics': 'RITUXAN (rituximab for injection)'}}, {'id': 'hc:178', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': '2000-03-17', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-06-02', 'url': 'https://pdf.hres.ca/dpd_pm/00071131.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 383, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 54, 'type': 'CategoricalVariant', 'name': 'CD20 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 82, 'membershipOperator': 'AND', 'therapies': [59, 2, 60, 122, 61]}, 'therapies': [{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primary_coding_id': 'ncit:C405', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primary_coding_id': 'ncit:C456', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primary_coding_id': 'ncit:C1702', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primary_coding_id': 'ncit:C770', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primary_coding_id': 'ncit:C933', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 77, 'conceptType': 'Disease', 'name': 'Diffuse Large B-Cell Lymphoma', 'primary_coding_id': 'oncotree:DLBCLNOS', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rituxan:1', 'document_id': 'doc:hc.rituxan', 'indication': 'RITUXAN (rituximab for injection) is indicated for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkins lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved rituximab for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkins lymphoma (DLBCL) in combination with CHOP chemotherapy.', 'raw_biomarkers': 'CD20 positive', 'raw_cancer_type': 'diffuse large B-cell non-Hodgkins lymphoma (DLBCL)', 'raw_therapeutics': 'RITUXAN (rituximab for injection), CHOP chemotherapy'}}, {'id': 'hc:179', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': '2000-03-17', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-06-02', 'url': 'https://pdf.hres.ca/dpd_pm/00071131.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 622, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 54, 'type': 'CategoricalVariant', 'name': 'CD20 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 124, 'membershipOperator': 'AND', 'therapies': [59, 60, 2, 8, 61]}, 'therapies': [{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primary_coding_id': 'ncit:C405', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primary_coding_id': 'ncit:C1702', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primary_coding_id': 'ncit:C456', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primary_coding_id': 'ncit:C769', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primary_coding_id': 'ncit:C933', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 77, 'conceptType': 'Disease', 'name': 'Diffuse Large B-Cell Lymphoma', 'primary_coding_id': 'oncotree:DLBCLNOS', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rituxan:1', 'document_id': 'doc:hc.rituxan', 'indication': 'RITUXAN (rituximab for injection) is indicated for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkins lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved rituximab for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkins lymphoma (DLBCL) in combination with CHOP chemotherapy.', 'raw_biomarkers': 'CD20 positive', 'raw_cancer_type': 'diffuse large B-cell non-Hodgkins lymphoma (DLBCL)', 'raw_therapeutics': 'RITUXAN (rituximab for injection), CHOP chemotherapy'}}, {'id': 'hc:180', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': '2000-03-17', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-06-02', 'url': 'https://pdf.hres.ca/dpd_pm/00071131.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 818, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 54, 'type': 'CategoricalVariant', 'name': 'CD20 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 178, 'membershipOperator': 'AND', 'therapies': [59, 8, 60, 61]}, 'therapies': [{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primary_coding_id': 'ncit:C405', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primary_coding_id': 'ncit:C769', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primary_coding_id': 'ncit:C1702', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primary_coding_id': 'ncit:C933', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 20, 'conceptType': 'Disease', 'name': 'Follicular Lymphoma', 'primary_coding_id': 'oncotree:FL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rituxan:2', 'document_id': 'doc:hc.rituxan', 'indication': \"RITUXAN (rituximab for injection) is indicated for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.\", 'initial_approval_date': '', 'initial_approval_url': '', 'description': \"Health Canada approved rituximab for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP chemotherapy.\", 'raw_biomarkers': 'CD20 positive', 'raw_cancer_type': \"Stage III/IV follicular B-cell non-Hodgkin's lymphoma\", 'raw_therapeutics': 'RITUXAN (rituximab for injection), CVP chemotherapy'}}, {'id': 'hc:181', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rozlytrek', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rozlytrek (entrectinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rozlytrek', 'drug_name_generic': 'entrectinib', 'first_published': '2020-02-07', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-11-09', 'url': 'https://pdf.hres.ca/dpd_pm/00073345.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 121, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 63, 'type': 'CategoricalVariant', 'name': 'v::NTRK1', 'genes': [35], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 80, 'conceptType': 'Drug', 'name': 'Entrectinib', 'primary_coding_id': 'ncit:C114984', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'ROS1 inhibition', 'NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 5, 'conceptType': 'Disease', 'name': 'Any solid tumor', 'primary_coding_id': 'ncit:C132146', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rozlytrek:0', 'document_id': 'doc:hc.rozlytrek', 'indication': 'ROZLYTREK (entrectinib) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved entrectinib for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.', 'raw_biomarkers': 'NTRK gene fusion', 'raw_cancer_type': 'unresectable locally advanced or metastatic extracranial solid tumours', 'raw_therapeutics': 'Rozlytrek (entrectinib)'}}, {'id': 'hc:182', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rozlytrek', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rozlytrek (entrectinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rozlytrek', 'drug_name_generic': 'entrectinib', 'first_published': '2020-02-07', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-11-09', 'url': 'https://pdf.hres.ca/dpd_pm/00073345.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 122, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 64, 'type': 'CategoricalVariant', 'name': 'v::NTRK2', 'genes': [36], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 80, 'conceptType': 'Drug', 'name': 'Entrectinib', 'primary_coding_id': 'ncit:C114984', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'ROS1 inhibition', 'NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 5, 'conceptType': 'Disease', 'name': 'Any solid tumor', 'primary_coding_id': 'ncit:C132146', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rozlytrek:0', 'document_id': 'doc:hc.rozlytrek', 'indication': 'ROZLYTREK (entrectinib) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved entrectinib for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.', 'raw_biomarkers': 'NTRK gene fusion', 'raw_cancer_type': 'unresectable locally advanced or metastatic extracranial solid tumours', 'raw_therapeutics': 'Rozlytrek (entrectinib)'}}, {'id': 'hc:183', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rozlytrek', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rozlytrek (entrectinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rozlytrek', 'drug_name_generic': 'entrectinib', 'first_published': '2020-02-07', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-11-09', 'url': 'https://pdf.hres.ca/dpd_pm/00073345.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 123, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 65, 'type': 'CategoricalVariant', 'name': 'v::NTRK3', 'genes': [37], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 80, 'conceptType': 'Drug', 'name': 'Entrectinib', 'primary_coding_id': 'ncit:C114984', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'ROS1 inhibition', 'NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 5, 'conceptType': 'Disease', 'name': 'Any solid tumor', 'primary_coding_id': 'ncit:C132146', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rozlytrek:0', 'document_id': 'doc:hc.rozlytrek', 'indication': 'ROZLYTREK (entrectinib) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved entrectinib for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.', 'raw_biomarkers': 'NTRK gene fusion', 'raw_cancer_type': 'unresectable locally advanced or metastatic extracranial solid tumours', 'raw_therapeutics': 'Rozlytrek (entrectinib)'}}, {'id': 'hc:184', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rozlytrek', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rozlytrek (entrectinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Rozlytrek', 'drug_name_generic': 'entrectinib', 'first_published': '2020-02-07', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-11-09', 'url': 'https://pdf.hres.ca/dpd_pm/00073345.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 120, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 62, 'type': 'CategoricalVariant', 'name': 'v::ROS1', 'genes': [50], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 80, 'conceptType': 'Drug', 'name': 'Entrectinib', 'primary_coding_id': 'ncit:C114984', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'ROS1 inhibition', 'NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rozlytrek:1', 'document_id': 'doc:hc.rozlytrek', 'indication': 'ROZLYTREK (entrectinib) is indicated for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) not previously treated with crizotinib.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved entrectinib for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) not previously treated with crizotinib.', 'raw_biomarkers': 'ROS1-positive', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Rozlytrek (entrectinib)'}}, {'id': 'hc:185', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2022-03-30', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-01-13', 'url': 'https://pdf.hres.ca/dpd_pm/00078295.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 465, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 10, 'type': 'CategoricalVariant', 'name': 'EGFR Exon 19 (Deletion)', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': 19}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 86, 'membershipOperator': 'AND', 'therapies': [108, 37, 49]}, 'therapies': [{'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primary_coding_id': 'ncit:C124993', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primary_coding_id': 'ncit:C1282', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primary_coding_id': 'ncit:C61614', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rybrevant:0', 'document_id': 'doc:hc.rybrevant', 'indication': 'RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved amivantamab in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.', 'raw_biomarkers': 'EGFR Eexon 19 deletions or Exon 21 L858R substitution mutations', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Rybrevant (amivantamab), carboplatin, pemetrexed'}}, {'id': 'hc:186', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2022-03-30', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-01-13', 'url': 'https://pdf.hres.ca/dpd_pm/00078295.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 466, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 9, 'type': 'CategoricalVariant', 'name': 'EGFR p.L858R', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 21}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}, {'name': 'hgvsc', 'value': 'ENST00000275493.2:c.2573T>G'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 86, 'membershipOperator': 'AND', 'therapies': [108, 37, 49]}, 'therapies': [{'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primary_coding_id': 'ncit:C124993', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primary_coding_id': 'ncit:C1282', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primary_coding_id': 'ncit:C61614', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rybrevant:0', 'document_id': 'doc:hc.rybrevant', 'indication': 'RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved amivantamab in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.', 'raw_biomarkers': 'EGFR Eexon 19 deletions or Exon 21 L858R substitution mutations', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Rybrevant (amivantamab), carboplatin, pemetrexed'}}, {'id': 'hc:187', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2022-03-30', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-01-13', 'url': 'https://pdf.hres.ca/dpd_pm/00078295.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 26, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 86, 'type': 'CategoricalVariant', 'name': 'EGFR Exon 20 (Insertion)', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Insertion'}, {'name': 'exon', 'value': 20}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 6, 'membershipOperator': 'AND', 'therapies': [37, 49, 108]}, 'therapies': [{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primary_coding_id': 'ncit:C1282', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primary_coding_id': 'ncit:C61614', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primary_coding_id': 'ncit:C124993', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rybrevant:1', 'document_id': 'doc:hc.rybrevant', 'indication': 'RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic NSCLC with activating EGFR Exon 20 insertion mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations.', 'raw_biomarkers': 'EGFR Exon 20 insertion mutations', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Rybrevant (amivantamab), carboplatin, pemetrexed'}}, {'id': 'hc:188', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2022-03-30', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-01-13', 'url': 'https://pdf.hres.ca/dpd_pm/00078295.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 27, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 86, 'type': 'CategoricalVariant', 'name': 'EGFR Exon 20 (Insertion)', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Insertion'}, {'name': 'exon', 'value': 20}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primary_coding_id': 'ncit:C124993', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rybrevant:2', 'document_id': 'doc:hc.rybrevant', 'indication': 'RYBREVANT (amivantamab for injection) is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved amivantamab as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.', 'raw_biomarkers': 'EGFR Exon 20 insertion mutations', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Rybrevant (amivantamab)'}}, {'id': 'hc:189', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 208, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 66, 'type': 'CategoricalVariant', 'name': 'FLT3-ITD', 'genes': [26], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Internal Tandem Duplication (ITD)'}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 40, 'membershipOperator': 'AND', 'therapies': [63, 68, 82]}, 'therapies': [{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primary_coding_id': 'ncit:C408', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primary_coding_id': 'ncit:C62091', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primary_coding_id': 'ncit:C1872', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 1, 'conceptType': 'Disease', 'name': 'Acute Myeloid Leukemia', 'primary_coding_id': 'oncotree:AML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rydapt:0', 'document_id': 'doc:hc.rydapt', 'indication': 'RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'raw_biomarkers': 'FLT3 mutation', 'raw_cancer_type': 'acute myeloid leukemia (AML)', 'raw_therapeutics': 'Rydapt (midostaurin), cytarabine, daunorubicin'}}, {'id': 'hc:190', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 209, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 85, 'type': 'CategoricalVariant', 'name': 'FLT3 p.D835Y', 'genes': [26], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.2503G>T'}, {'name': 'protein_change', 'value': 'p.D835Y'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>A'}, {'name': 'hgvsc', 'value': 'ENST00000241453.7:c.2503G>T'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 40, 'membershipOperator': 'AND', 'therapies': [63, 68, 82]}, 'therapies': [{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primary_coding_id': 'ncit:C408', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primary_coding_id': 'ncit:C62091', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primary_coding_id': 'ncit:C1872', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 1, 'conceptType': 'Disease', 'name': 'Acute Myeloid Leukemia', 'primary_coding_id': 'oncotree:AML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rydapt:0', 'document_id': 'doc:hc.rydapt', 'indication': 'RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'raw_biomarkers': 'FLT3 mutation', 'raw_cancer_type': 'acute myeloid leukemia (AML)', 'raw_therapeutics': 'Rydapt (midostaurin), cytarabine, daunorubicin'}}, {'id': 'hc:191', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 210, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 116, 'type': 'CategoricalVariant', 'name': 'FLT3 p.D835A', 'genes': [26], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592641}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2504A>C'}, {'name': 'protein_change', 'value': 'p.D835A'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 20}, {'name': 'rsid', 'value': 'rs121909646'}, {'name': 'hgvsg', 'value': '13:g.28592641T>G'}, {'name': 'hgvsc', 'value': 'ENST00000241453.7:c.2504A>C'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 40, 'membershipOperator': 'AND', 'therapies': [63, 68, 82]}, 'therapies': [{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primary_coding_id': 'ncit:C408', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primary_coding_id': 'ncit:C62091', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primary_coding_id': 'ncit:C1872', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 1, 'conceptType': 'Disease', 'name': 'Acute Myeloid Leukemia', 'primary_coding_id': 'oncotree:AML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rydapt:0', 'document_id': 'doc:hc.rydapt', 'indication': 'RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'raw_biomarkers': 'FLT3 mutation', 'raw_cancer_type': 'acute myeloid leukemia (AML)', 'raw_therapeutics': 'Rydapt (midostaurin), cytarabine, daunorubicin'}}, {'id': 'hc:192', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 211, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 117, 'type': 'CategoricalVariant', 'name': 'FLT3 p.D835E', 'genes': [26], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592640}, {'name': 'end_position', 'value': 28592640}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.2505T>G'}, {'name': 'protein_change', 'value': 'p.D835E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 20}, {'name': 'rsid', 'value': 'rs121913487'}, {'name': 'hgvsg', 'value': '13:g.28592640A>C'}, {'name': 'hgvsc', 'value': 'ENST00000241453.7:c.2505T>G'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 40, 'membershipOperator': 'AND', 'therapies': [63, 68, 82]}, 'therapies': [{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primary_coding_id': 'ncit:C408', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primary_coding_id': 'ncit:C62091', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primary_coding_id': 'ncit:C1872', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 1, 'conceptType': 'Disease', 'name': 'Acute Myeloid Leukemia', 'primary_coding_id': 'oncotree:AML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rydapt:0', 'document_id': 'doc:hc.rydapt', 'indication': 'RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'raw_biomarkers': 'FLT3 mutation', 'raw_cancer_type': 'acute myeloid leukemia (AML)', 'raw_therapeutics': 'Rydapt (midostaurin), cytarabine, daunorubicin'}}, {'id': 'hc:193', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 212, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 118, 'type': 'CategoricalVariant', 'name': 'FLT3 p.D835H', 'genes': [26], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2503G>C'}, {'name': 'protein_change', 'value': 'p.D835H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 20}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>G'}, {'name': 'hgvsc', 'value': 'ENST00000241453.7:c.2503G>C'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 40, 'membershipOperator': 'AND', 'therapies': [63, 68, 82]}, 'therapies': [{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primary_coding_id': 'ncit:C408', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primary_coding_id': 'ncit:C62091', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primary_coding_id': 'ncit:C1872', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 1, 'conceptType': 'Disease', 'name': 'Acute Myeloid Leukemia', 'primary_coding_id': 'oncotree:AML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rydapt:0', 'document_id': 'doc:hc.rydapt', 'indication': 'RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'raw_biomarkers': 'FLT3 mutation', 'raw_cancer_type': 'acute myeloid leukemia (AML)', 'raw_therapeutics': 'Rydapt (midostaurin), cytarabine, daunorubicin'}}, {'id': 'hc:194', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 213, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 119, 'type': 'CategoricalVariant', 'name': 'FLT3 p.D835N', 'genes': [26], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.2503G>A'}, {'name': 'protein_change', 'value': 'p.D835N'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 20}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>T'}, {'name': 'hgvsc', 'value': 'ENST00000241453.7:c.2503G>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 40, 'membershipOperator': 'AND', 'therapies': [63, 68, 82]}, 'therapies': [{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primary_coding_id': 'ncit:C408', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primary_coding_id': 'ncit:C62091', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primary_coding_id': 'ncit:C1872', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 1, 'conceptType': 'Disease', 'name': 'Acute Myeloid Leukemia', 'primary_coding_id': 'oncotree:AML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rydapt:0', 'document_id': 'doc:hc.rydapt', 'indication': 'RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'raw_biomarkers': 'FLT3 mutation', 'raw_cancer_type': 'acute myeloid leukemia (AML)', 'raw_therapeutics': 'Rydapt (midostaurin), cytarabine, daunorubicin'}}, {'id': 'hc:195', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 214, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 120, 'type': 'CategoricalVariant', 'name': 'FLT3 p.D835S', 'genes': [26], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'TC'}, {'name': 'alternate_allele', 'value': 'CT'}, {'name': 'cdna_change', 'value': 'c.2503_2504delinsAG'}, {'name': 'protein_change', 'value': 'p.D835S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 20}, {'name': 'rsid', 'value': 'ENST00000241453.7:c.2503_2504delinsAG'}, {'name': 'hgvsg', 'value': '13:g.28592641_28592642delinsCT'}, {'name': 'hgvsc', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 40, 'membershipOperator': 'AND', 'therapies': [63, 68, 82]}, 'therapies': [{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primary_coding_id': 'ncit:C408', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primary_coding_id': 'ncit:C62091', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primary_coding_id': 'ncit:C1872', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 1, 'conceptType': 'Disease', 'name': 'Acute Myeloid Leukemia', 'primary_coding_id': 'oncotree:AML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rydapt:0', 'document_id': 'doc:hc.rydapt', 'indication': 'RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'raw_biomarkers': 'FLT3 mutation', 'raw_cancer_type': 'acute myeloid leukemia (AML)', 'raw_therapeutics': 'Rydapt (midostaurin), cytarabine, daunorubicin'}}, {'id': 'hc:196', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 215, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 121, 'type': 'CategoricalVariant', 'name': 'FLT3 p.D835V', 'genes': [26], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592641}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.2504A>T'}, {'name': 'protein_change', 'value': 'p.D835V'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 20}, {'name': 'rsid', 'value': 'rs121909646'}, {'name': 'hgvsg', 'value': '13:g.28592641T>A'}, {'name': 'hgvsc', 'value': 'ENST00000241453.7:c.2504A>T'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 40, 'membershipOperator': 'AND', 'therapies': [63, 68, 82]}, 'therapies': [{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primary_coding_id': 'ncit:C408', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primary_coding_id': 'ncit:C62091', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primary_coding_id': 'ncit:C1872', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 1, 'conceptType': 'Disease', 'name': 'Acute Myeloid Leukemia', 'primary_coding_id': 'oncotree:AML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rydapt:0', 'document_id': 'doc:hc.rydapt', 'indication': 'RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'raw_biomarkers': 'FLT3 mutation', 'raw_cancer_type': 'acute myeloid leukemia (AML)', 'raw_therapeutics': 'Rydapt (midostaurin), cytarabine, daunorubicin'}}, {'id': 'hc:197', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 216, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 123, 'type': 'CategoricalVariant', 'name': 'FLT3 p.I836del', 'genes': [26], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592635}, {'name': 'end_position', 'value': 28592637}, {'name': 'reference_allele', 'value': 'ATG'}, {'name': 'alternate_allele', 'value': '-'}, {'name': 'cdna_change', 'value': 'c.2508_2510del'}, {'name': 'protein_change', 'value': 'p.I836del'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': 20}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': '13:g.28592635_28592637del'}, {'name': 'hgvsc', 'value': 'ENST00000241453.7:c.2508_2510del'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 40, 'membershipOperator': 'AND', 'therapies': [63, 68, 82]}, 'therapies': [{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primary_coding_id': 'ncit:C408', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primary_coding_id': 'ncit:C62091', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primary_coding_id': 'ncit:C1872', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 1, 'conceptType': 'Disease', 'name': 'Acute Myeloid Leukemia', 'primary_coding_id': 'oncotree:AML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rydapt:0', 'document_id': 'doc:hc.rydapt', 'indication': 'RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'raw_biomarkers': 'FLT3 mutation', 'raw_cancer_type': 'acute myeloid leukemia (AML)', 'raw_therapeutics': 'Rydapt (midostaurin), cytarabine, daunorubicin'}}, {'id': 'hc:198', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': '2017-07-21', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00070168.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 723, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 66, 'type': 'CategoricalVariant', 'name': 'FLT3-ITD', 'genes': [26], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Internal Tandem Duplication (ITD)'}, {'name': 'exon', 'value': None}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 149, 'membershipOperator': 'AND', 'therapies': [82, 68, 63]}, 'therapies': [{'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primary_coding_id': 'ncit:C1872', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primary_coding_id': 'ncit:C62091', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primary_coding_id': 'ncit:C408', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 1, 'conceptType': 'Disease', 'name': 'Acute Myeloid Leukemia', 'primary_coding_id': 'oncotree:AML', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.rydapt:0', 'document_id': 'doc:hc.rydapt', 'indication': 'RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).', 'raw_biomarkers': 'FLT3 mutation', 'raw_cancer_type': 'acute myeloid leukemia (AML)', 'raw_therapeutics': 'Rydapt (midostaurin), cytarabine, daunorubicin'}}, {'id': 'hc:199', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.scemblix', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Scemblix (asciminib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Scemblix (asciminib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076300.PDF. Revised July 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc', 'drug_name_brand': 'Scemblix', 'drug_name_generic': 'asciminib', 'first_published': '2022-06-21', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-07-12', 'url': 'https://pdf.hres.ca/dpd_pm/00076300.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101756', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.scemblix:0', 'document_id': 'doc:hc.scemblix', 'indication': 'SCEMBLIXTM (asciminib tablets) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors.', 'raw_biomarkers': 'Philadelphia chromosome-positive (Ph+)', 'raw_cancer_type': 'chronic myeloid leukemia (CML)', 'raw_therapeutics': 'Scemblix (asciminib)'}, 'proposition': None}, {'id': 'hc:200', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.sprycel', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Sprycel (dasatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Sprycel (dasatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063441.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Sprycel', 'drug_name_generic': 'dasatinib', 'first_published': '2007-03-22', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-11-03', 'url': 'https://pdf.hres.ca/dpd_pm/00063441.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77850', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.sprycel:0', 'document_id': 'doc:hc.sprycel', 'indication': 'SPRYCEL (dasatinib) is indicated for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dasatinib for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.', 'raw_biomarkers': 'Philadelphia chromosome positive (Ph+)', 'raw_cancer_type': 'chronic myeloid leukemia (CML) in chronic phase', 'raw_therapeutics': 'Sprycel (dasatinib)'}, 'proposition': None}, {'id': 'hc:201', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.sprycel', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Sprycel (dasatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Sprycel (dasatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063441.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Sprycel', 'drug_name_generic': 'dasatinib', 'first_published': '2007-03-22', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-11-03', 'url': 'https://pdf.hres.ca/dpd_pm/00063441.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77850', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.sprycel:1', 'document_id': 'doc:hc.sprycel', 'indication': 'SPRYCEL (dasatinib) is indicated for the treatment of adults with Ph+ chronic, accelerated, or blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dasatinib for the treatment of adults with Ph+ chronic, accelerated, or blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate.', 'raw_biomarkers': 'Philadelphia chromosome positive (Ph+)', 'raw_cancer_type': 'chronic, accelerated, or blast phase chronic myeloid leukemia (CML)', 'raw_therapeutics': 'Sprycel (dasatinib)'}, 'proposition': None}, {'id': 'hc:202', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.sprycel', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Sprycel (dasatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Sprycel (dasatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063441.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Sprycel', 'drug_name_generic': 'dasatinib', 'first_published': '2007-03-22', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-11-03', 'url': 'https://pdf.hres.ca/dpd_pm/00063441.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77850', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.sprycel:2', 'document_id': 'doc:hc.sprycel', 'indication': 'SPRYCEL (dasatinib) is indicated for the treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dasatinib for the treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.', 'raw_biomarkers': 'Philadelphia chromosome positive (Ph+)', 'raw_cancer_type': 'acute lymphoblastic leukemia (ALL)', 'raw_therapeutics': 'Sprycel (dasatinib)'}, 'proposition': None}, {'id': 'hc:203', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tabrecta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tabrecta (capmatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tabrecta (capmatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071417.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tabrecta', 'drug_name_generic': 'capmatinib', 'first_published': '2022-05-19', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-06-26', 'url': 'https://pdf.hres.ca/dpd_pm/00071417.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101646', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 73, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 67, 'type': 'CategoricalVariant', 'name': 'MET Exon 14 (Splice Site)', 'genes': [32], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Splice Site'}, {'name': 'exon', 'value': 14}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 85, 'conceptType': 'Drug', 'name': 'Capmatinib', 'primary_coding_id': 'ncit:C90564', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tabrecta:0', 'document_id': 'doc:hc.tabrecta', 'indication': 'TABRECTA (capmatinib tablets) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved capmatinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.', 'raw_biomarkers': 'MET exon 14 skipping', 'raw_cancer_type': ' locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tabrecta (capmatinib)'}}, {'id': 'hc:204', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tabrecta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tabrecta (capmatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tabrecta (capmatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071417.PDF. Revised June 2023. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tabrecta', 'drug_name_generic': 'capmatinib', 'first_published': '2022-05-19', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2023-06-26', 'url': 'https://pdf.hres.ca/dpd_pm/00071417.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101646', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 74, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 68, 'type': 'CategoricalVariant', 'name': 'MET Exon 14 (Deletion)', 'genes': [32], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': 14}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 85, 'conceptType': 'Drug', 'name': 'Capmatinib', 'primary_coding_id': 'ncit:C90564', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tabrecta:0', 'document_id': 'doc:hc.tabrecta', 'indication': 'TABRECTA (capmatinib tablets) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved capmatinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.', 'raw_biomarkers': 'MET exon 14 skipping', 'raw_cancer_type': ' locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tabrecta (capmatinib)'}}, {'id': 'hc:205', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': '2013-08-23', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077956.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 88, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 16, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600E', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1799T>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primary_coding_id': 'ncit:C82386', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 40, 'conceptType': 'Disease', 'name': 'Melanoma', 'primary_coding_id': 'oncotree:MEL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tafinlar:0', 'document_id': 'doc:hc.tafinlar', 'indication': 'TAFINLAR (dabrafenib mesylate) is indicated as a monotherapy, or in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dabrafenib as a monotherapy, or in combination with trametinib, for the treatment of patients with the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'raw_biomarkers': 'unresectable or metastatic melanoma', 'raw_cancer_type': 'BRAF V600 mutation', 'raw_therapeutics': 'Tafinlar (dabrafenib mesylate)'}}, {'id': 'hc:206', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': '2013-08-23', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077956.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 663, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 17, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600K', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1798_1799delinsAA'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primary_coding_id': 'ncit:C82386', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 40, 'conceptType': 'Disease', 'name': 'Melanoma', 'primary_coding_id': 'oncotree:MEL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tafinlar:0', 'document_id': 'doc:hc.tafinlar', 'indication': 'TAFINLAR (dabrafenib mesylate) is indicated as a monotherapy, or in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dabrafenib as a monotherapy, or in combination with trametinib, for the treatment of patients with the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'raw_biomarkers': 'unresectable or metastatic melanoma', 'raw_cancer_type': 'BRAF V600 mutation', 'raw_therapeutics': 'Tafinlar (dabrafenib mesylate)'}}, {'id': 'hc:207', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': '2013-08-23', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077956.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tafinlar:1', 'document_id': 'doc:hc.tafinlar', 'indication': 'TAFINLAR (dabrafenib mesylate), in combination with trametinib, is indicated for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph node(s), following complete resection.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dabrafenib mesylate, in combination with trametinib for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph node(s), following complete resection.', 'raw_biomarkers': 'BRAF V600E or V600K', 'raw_cancer_type': 'melanoma', 'raw_therapeutics': 'Tafinlar (dabrafenib mesylate), trametinib'}, 'proposition': None}, {'id': 'hc:208', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': '2013-08-23', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077956.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tafinlar:1', 'document_id': 'doc:hc.tafinlar', 'indication': 'TAFINLAR (dabrafenib mesylate), in combination with trametinib, is indicated for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph node(s), following complete resection.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dabrafenib mesylate, in combination with trametinib for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph node(s), following complete resection.', 'raw_biomarkers': 'BRAF V600E or V600K', 'raw_cancer_type': 'melanoma', 'raw_therapeutics': 'Tafinlar (dabrafenib mesylate), trametinib'}, 'proposition': None}, {'id': 'hc:209', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': '2013-08-23', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077956.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 91, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 16, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600E', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1799T>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 18, 'membershipOperator': 'AND', 'therapies': [67, 66]}, 'therapies': [{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primary_coding_id': 'ncit:C82386', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primary_coding_id': 'ncit:C77908', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tafinlar:2', 'document_id': 'doc:hc.tafinlar', 'indication': 'TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.', 'raw_biomarkers': 'BRAF V600E', 'raw_cancer_type': 'metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tafinlar (dabrafenib mesylate), trametinib'}}, {'id': 'hc:210', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': '2013-08-23', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077956.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 94, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 16, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600E', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1799T>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 18, 'membershipOperator': 'AND', 'therapies': [67, 66]}, 'therapies': [{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primary_coding_id': 'ncit:C82386', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primary_coding_id': 'ncit:C77908', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 35, 'conceptType': 'Disease', 'name': 'Low-Grade Glioma, NOS', 'primary_coding_id': 'oncotree:LGGNOS', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tafinlar:3', 'document_id': 'doc:hc.tafinlar', 'indication': 'TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.', 'raw_biomarkers': 'BRAF V600E', 'raw_cancer_type': 'low-grade glioma (LGG)', 'raw_therapeutics': 'Tafinlar (dabrafenib mesylate), trametinib'}}, {'id': 'hc:211', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': '2013-08-23', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-12-05', 'url': 'https://pdf.hres.ca/dpd_pm/00077956.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 660, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 16, 'type': 'CategoricalVariant', 'name': 'BRAF p.V600E', 'genes': [8], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 15}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}, {'name': 'hgvsc', 'value': 'ENST00000288602.6:c.1799T>A'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 18, 'membershipOperator': 'AND', 'therapies': [67, 66]}, 'therapies': [{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primary_coding_id': 'ncit:C82386', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primary_coding_id': 'ncit:C77908', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 83, 'conceptType': 'Disease', 'name': 'High-Grade Glioma, NOS', 'primary_coding_id': 'oncotree:HGGNOS', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tafinlar:4', 'document_id': 'doc:hc.tafinlar', 'indication': 'TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of pediatric patients 1 year of age and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of pediatric patients 1 year of age and older with high-grade glioma (HGG) with BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.', 'raw_biomarkers': 'BRAF V600E', 'raw_cancer_type': 'high-grade glioma (HGG)', 'raw_therapeutics': 'Tafinalr (dabrafenib mesylate), trametinib'}}, {'id': 'hc:212', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 304, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 10, 'type': 'CategoricalVariant', 'name': 'EGFR Exon 19 (Deletion)', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': 19}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primary_coding_id': 'ncit:C116377', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tagrisso:0', 'document_id': 'doc:hc.tagrisso', 'indication': 'TAGRISSO (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved osimertinib as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R substitution', 'raw_cancer_type': 'stage IB-IIIA1 non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tagrisso (osimertinib)'}}, {'id': 'hc:212', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 305, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 9, 'type': 'CategoricalVariant', 'name': 'EGFR p.L858R', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 21}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}, {'name': 'hgvsc', 'value': 'ENST00000275493.2:c.2573T>G'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primary_coding_id': 'ncit:C116377', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tagrisso:0', 'document_id': 'doc:hc.tagrisso', 'indication': 'TAGRISSO (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved osimertinib as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R substitution', 'raw_cancer_type': 'stage IB-IIIA1 non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tagrisso (osimertinib)'}}, {'id': 'hc:213', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 304, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 10, 'type': 'CategoricalVariant', 'name': 'EGFR Exon 19 (Deletion)', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': 19}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primary_coding_id': 'ncit:C116377', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tagrisso:1', 'document_id': 'doc:hc.tagrisso', 'indication': 'TAGRISSO (osimertinib) is indicated for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum based chemoradiation therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved osimertinib for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during opr following platinum based chemoradiation therapy.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R substitution', 'raw_cancer_type': 'locally advanced, unresectable non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tagrisso (osimertinib)'}}, {'id': 'hc:214', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 305, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 9, 'type': 'CategoricalVariant', 'name': 'EGFR p.L858R', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 21}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}, {'name': 'hgvsc', 'value': 'ENST00000275493.2:c.2573T>G'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primary_coding_id': 'ncit:C116377', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tagrisso:1', 'document_id': 'doc:hc.tagrisso', 'indication': 'TAGRISSO (osimertinib) is indicated for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum based chemoradiation therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved osimertinib for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during opr following platinum based chemoradiation therapy.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R substitution', 'raw_cancer_type': 'locally advanced, unresectable non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tagrisso (osimertinib)'}}, {'id': 'hc:215', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 304, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 10, 'type': 'CategoricalVariant', 'name': 'EGFR Exon 19 (Deletion)', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': 19}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primary_coding_id': 'ncit:C116377', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tagrisso:2', 'document_id': 'doc:hc.tagrisso', 'indication': 'TAGRISSO (osimertinib) is indicated for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved osimertinib for the first-line  treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R substitution', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tagrisso (osimertinib)'}}, {'id': 'hc:216', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 305, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 9, 'type': 'CategoricalVariant', 'name': 'EGFR p.L858R', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 21}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}, {'name': 'hgvsc', 'value': 'ENST00000275493.2:c.2573T>G'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primary_coding_id': 'ncit:C116377', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tagrisso:2', 'document_id': 'doc:hc.tagrisso', 'indication': 'TAGRISSO (osimertinib) is indicated for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved osimertinib for the first-line  treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R substitution', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tagrisso (osimertinib)'}}, {'id': 'hc:217', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 306, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 9, 'type': 'CategoricalVariant', 'name': 'EGFR p.L858R', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 21}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}, {'name': 'hgvsc', 'value': 'ENST00000275493.2:c.2573T>G'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 47, 'membershipOperator': 'AND', 'therapies': [39, 86, 49]}, 'therapies': [{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primary_coding_id': 'ncit:C376', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primary_coding_id': 'ncit:C116377', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primary_coding_id': 'ncit:C61614', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tagrisso:3', 'document_id': 'doc:hc.tagrisso', 'indication': 'TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R substitution', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tagrisso (osimertinib), pemetrexed, platinum-based chemotherapy'}}, {'id': 'hc:218', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 307, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 9, 'type': 'CategoricalVariant', 'name': 'EGFR p.L858R', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 21}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}, {'name': 'hgvsc', 'value': 'ENST00000275493.2:c.2573T>G'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 48, 'membershipOperator': 'AND', 'therapies': [37, 86, 49]}, 'therapies': [{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primary_coding_id': 'ncit:C1282', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primary_coding_id': 'ncit:C116377', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primary_coding_id': 'ncit:C61614', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tagrisso:3', 'document_id': 'doc:hc.tagrisso', 'indication': 'TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R substitution', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tagrisso (osimertinib), pemetrexed, platinum-based chemotherapy'}}, {'id': 'hc:219', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 308, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 10, 'type': 'CategoricalVariant', 'name': 'EGFR Exon 19 (Deletion)', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': 19}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 48, 'membershipOperator': 'AND', 'therapies': [37, 86, 49]}, 'therapies': [{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primary_coding_id': 'ncit:C1282', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primary_coding_id': 'ncit:C116377', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primary_coding_id': 'ncit:C61614', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tagrisso:3', 'document_id': 'doc:hc.tagrisso', 'indication': 'TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R substitution', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tagrisso (osimertinib), pemetrexed, platinum-based chemotherapy'}}, {'id': 'hc:220', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 309, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 10, 'type': 'CategoricalVariant', 'name': 'EGFR Exon 19 (Deletion)', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': 19}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_id': None, 'therapy_group': {'id': 47, 'membershipOperator': 'AND', 'therapies': [39, 86, 49]}, 'therapies': [{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primary_coding_id': 'ncit:C376', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primary_coding_id': 'ncit:C116377', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primary_coding_id': 'ncit:C61614', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}], 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tagrisso:3', 'document_id': 'doc:hc.tagrisso', 'indication': 'TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R substitution', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tagrisso (osimertinib), pemetrexed, platinum-based chemotherapy'}}, {'id': 'hc:221', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2016-07-05', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-04-23', 'url': 'https://pdf.hres.ca/dpd_pm/00080336.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 310, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 70, 'type': 'CategoricalVariant', 'name': 'EGFR p.T790M', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55249071}, {'name': 'end_position', 'value': 55249071}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.2369C>T'}, {'name': 'protein_change', 'value': 'p.T790M'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 20}, {'name': 'rsid', 'value': 'rs121434569'}, {'name': 'hgvsg', 'value': '7:g.55249071C>T'}, {'name': 'hgvsc', 'value': 'ENST00000275493.2:c.2369C>T'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primary_coding_id': 'ncit:C116377', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tagrisso:4', 'document_id': 'doc:hc.tagrisso', 'indication': 'TAGRISSO (osimertinib) is indicated for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved osimertinib for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.', 'raw_biomarkers': 'EGFR T790M', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Tagrisso (osimertinib)'}}, {'id': 'hc:222', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tasigna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tasigna (nilotinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tasigna (nilotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076372.PDF. Revised July 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tasigna', 'drug_name_generic': 'nilotinib', 'first_published': '2008-09-30', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-07-17', 'url': 'https://pdf.hres.ca/dpd_pm/00076372.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80138', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tasigna:0', 'document_id': 'doc:hc.tasinga', 'indication': 'TASIGNA (nilotinib) 150 mg and 200 mg capsules are indicated for The treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nilotinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).', 'raw_biomarkers': 'philadelphia chromosome-positive (Ph+)', 'raw_cancer_type': 'chronic myeloid leukemia (CML)', 'raw_therapeutics': 'Tasigna (nilotinib)'}, 'proposition': None}, {'id': 'hc:223', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tasigna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tasigna (nilotinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tasigna (nilotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076372.PDF. Revised July 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tasigna', 'drug_name_generic': 'nilotinib', 'first_published': '2008-09-30', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-07-17', 'url': 'https://pdf.hres.ca/dpd_pm/00076372.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80138', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tasigna:1', 'document_id': 'doc:hc.tasigna', 'indication': 'TASIGNA (nilotinib) 150mg and 200mg capsules are indicated for the treatment of pediatric patients 2 years of age and older with newly diagnosed Ph+ CML-CP.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved tasigna for the treatment of the treatment of pediatric patients 2 years of age and older with newly diagnosed Ph+ CML-CP.', 'raw_biomarkers': 'philadelphia chromosome-positive (Ph+)', 'raw_cancer_type': 'chronic myeloid leukemia (CML)', 'raw_therapeutics': 'Tasigna (nilotinib)'}, 'proposition': None}, {'id': 'hc:224', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tasigna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tasigna (nilotinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tasigna (nilotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076372.PDF. Revised July 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tasigna', 'drug_name_generic': 'nilotinib', 'first_published': '2008-09-30', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-07-17', 'url': 'https://pdf.hres.ca/dpd_pm/00076372.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80138', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tasigna:2', 'document_id': 'doc:hc.tasigna', 'indication': 'TASIGNA (nilotinib) 150 mg and 200 mg capsules are indicated for the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in adult patients resistant to or intolerant of at least one prior therapy including imatinib.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nilotinib for The treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in adult patients resistant to or intolerant of at least one prior therapy including imatinib', 'raw_biomarkers': 'philadelphia chromosome-positive (Ph+)', 'raw_cancer_type': 'chronic myeloid leukemia (CML)', 'raw_therapeutics': 'Tasigna (nilotinib)'}, 'proposition': None}, {'id': 'hc:225', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.tasigna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tasigna (nilotinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Tasigna (nilotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076372.PDF. Revised July 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Tasigna', 'drug_name_generic': 'nilotinib', 'first_published': '2008-09-30', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-07-17', 'url': 'https://pdf.hres.ca/dpd_pm/00076372.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80138', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.tasigna:3', 'document_id': 'doc:hc.tasigna', 'indication': 'TASIGNA (nilotinib) 150 mg and 200 mg capsules are indicated for the treatment of pediatric patients 2 years of age and older with Ph+ CML-CP with resistance or intolerance to prior therapy including imatinib.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved nilotinib for the treatment of pediatric patients 2 years of age and older with Ph+ CML-CP with resistance or intolerance to prior therapy including imatinib.', 'raw_biomarkers': 'philadelphia chromosome-positive (Ph+)', 'raw_cancer_type': 'chronic myeloid leukemia (CML)', 'raw_therapeutics': 'Tasigna (nilotinib)'}, 'proposition': None}]\n"
     ]
    }
   ],
   "source": [
    "print(\"the amount of null statements is: \" + str(null_count))\n",
    "print(\"the amount of 'correct' statements is: \" + str(statement_count))\n",
    "dereference_statements1 = dereference_statements(statements, dereferenced_prop_lookup, strength_lookup, indication_lookup, contribution_lookup, document_lookup)\n",
    "print(dereference_statements1)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "moalmanac-db",
   "language": "python",
   "name": "moalmanac-db"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
